1
|
Gorgolis G, Kotsidi M, Paterakis G, Koutroumanis N, Tsakonas C, Galiotis C. Graphene aerogels as efficient adsorbers of water pollutants and their effect of drying methods. Sci Rep 2024; 14:8029. [PMID: 38580774 PMCID: PMC10997784 DOI: 10.1038/s41598-024-58651-1] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/08/2024] [Accepted: 04/02/2024] [Indexed: 04/07/2024] Open
Abstract
Environmental accidents highlight the need for the development of efficient materials that can be employed to eliminate pollutants including crude oil and its derivatives, as well as toxic organic solvents. In recent years, a wide variety of advanced materials has been investigated to assist in the purification process of environmentally compromised regions, with the principal contestants being graphene-based structures. This study describes the synthesis of graphene aerogels with two methods and determines their efficiency as adsorbents of several water pollutants. The main difference between the two synthesis routes is the use of freeze-drying in the first case, and ambient pressure drying in the latter. Raman spectroscopy, Scanning Electron Microscopy (SEM), X-ray diffraction (XRD), X-ray Photoelectron Spectroscopy (XPS) and contact angle measurements are employed here for the characterisation of the samples. The as-prepared aerogels have been found to act as photocatalysts of aqueous dye solutions like methylene blue and Orange G, while they were also evaluated as adsorbents of organic solvents (acetone, ethanol and methanol), and, oils like pump oil, castor oil, silicone oil, as well. The results presented here show that the freeze-drying approach provides materials with better adsorption efficiency for the most of the examined pollutants, however, the energy and cost-saving advantages of ambient-pressure-drying could offset the adsorption advantages of the former case.
Collapse
Affiliation(s)
- G Gorgolis
- Department of Chemical Engineering, University of Patras, 26504, Patras, Greece.
- Foundation for Research and Technology - Hellas (FORTH/ ICE-HT), Institute of Chemical Engineering Sciences, 26504, Patras, Greece.
| | - M Kotsidi
- Department of Chemical Engineering, University of Patras, 26504, Patras, Greece
| | - G Paterakis
- Department of Chemical Engineering, University of Patras, 26504, Patras, Greece
- Foundation for Research and Technology - Hellas (FORTH/ ICE-HT), Institute of Chemical Engineering Sciences, 26504, Patras, Greece
| | - N Koutroumanis
- Foundation for Research and Technology - Hellas (FORTH/ ICE-HT), Institute of Chemical Engineering Sciences, 26504, Patras, Greece
| | - C Tsakonas
- Foundation for Research and Technology - Hellas (FORTH/ ICE-HT), Institute of Chemical Engineering Sciences, 26504, Patras, Greece
| | - C Galiotis
- Department of Chemical Engineering, University of Patras, 26504, Patras, Greece.
- Foundation for Research and Technology - Hellas (FORTH/ ICE-HT), Institute of Chemical Engineering Sciences, 26504, Patras, Greece.
| |
Collapse
|
2
|
Ampatzidou M, Papadhimitriou SI, Paisiou A, Paterakis G, Tzanoudaki M, Papadakis V, Florentin L, Polychronopoulou S. The Prognostic Effect of CDKN2A/2B Gene Deletions in Pediatric Acute Lymphoblastic Leukemia (ALL): Independent Prognostic Significance in BFM-Based Protocols. Diagnostics (Basel) 2023; 13:diagnostics13091589. [PMID: 37174980 PMCID: PMC10178600 DOI: 10.3390/diagnostics13091589] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/31/2023] [Revised: 04/21/2023] [Accepted: 04/27/2023] [Indexed: 05/15/2023] Open
Abstract
One of the most frequent genes affected in pediatric ALL is the CDKN2A/2B gene, acting as a secondary cooperating event and playing an important role in cell-cycle regulation and chemosensitivity. Despite its inclusion in combined CNA (copy-number alterations) classifiers, like the IKZF1plus entity and the UKALL CNA profile, the prognostic impact of the individual gene deletions outside the context of a combined CNA evaluation remains controversial. Addressing the CDKN2A/2B deletions' additive prognostic effect in current risk-stratification algorithms, we present a retrospective study of a Greek pediatric ALL cohort comprising 247 patients studied over a 24-year period (2000-2023). Herein, we provide insight regarding the correlation with disease features, MRD clearance, and independent prognostic significance for this ALL cohort treated with contemporary BFM-based treatment protocols. Within an extended follow-up time of 135 months, the presence of the CDKN2A/2B deletions (biallelic or monoallelic) was associated with inferior EFS rates (65.1% compared to 91.8% for the gene non-deleted subgroup, p < 0.001), with the relapse rate accounting for 22.2% and 5.9%, respectively (p < 0.001). The presence of the biallelic deletion was associated with the worst outcomes (EFS 57.2% vs. 89.6% in the case of any other status, monoallelic or non-deleted, p < 0.001). Survival differences were demonstrated for B-ALL cases (EFS 65.3% vs. 93.6% for the non-deleted B-ALL subgroup, p < 0.001), but the prognostic effect was not statistically significant within the T-ALL cohort (EFS 64.3 vs. 69.2, p = 0.947). The presence of the CDKN2A/2B deletions clearly correlated with inferior outcomes within all protocol-defined risk groups (standard risk (SR): EFS 66.7% vs. 100%, p < 0.001, intermediate risk (IR): EFS 77.1% vs. 97.9%, p < 0.001, high risk (HR): EFS 42.1% vs. 70.5% p < 0.001 for deleted vs non-deleted cases in each patient risk group); additionally, in this study, the presence of the deletion differentiated prognosis within both MRD-positive and -negative subgroups on days 15 and 33 of induction. In multivariate analysis, the presence of the CDKN2A/2B deletions was the most important prognostic factor for relapse and overall survival, yielding a hazard ratio of 5.2 (95% confidence interval: 2.59-10.41, p < 0.001) and 5.96 (95% confidence interval: 2.97-11.95, p < 0.001), respectively, designating the alteration's independent prognostic significance in the context of modern risk stratification. The results of our study demonstrate that the presence of the CDKN2A/2B deletions can further stratify all existing risk groups, identifying patient subgroups with different outcomes. The above biallelic deletions could be incorporated into future risk-stratification algorithms, refining MRD-based stratification. In the era of targeted therapies, future prospective controlled clinical trials will further explore the possible use of cyclin-dependent kinase inhibitors (CDKIs) in CDKN2A/2B-affected ALL pediatric subgroups.
Collapse
Affiliation(s)
- Mirella Ampatzidou
- Department of Pediatric Hematology-Oncology (TAO), "Aghia Sophia" Children's Hospital, 11527 Athens, Greece
| | - Stefanos I Papadhimitriou
- Laboratory of Hematology, Unit of Molecular Cytogenetics, "G. Gennimatas" General Hospital, 11527 Athens, Greece
| | - Anna Paisiou
- Bone Marrow Transplantation Unit, "Aghia Sophia" Children's Hospital, 11527 Athens, Greece
| | - Georgios Paterakis
- Laboratory of Flow Cytometry, Department of Immunology, "G. Gennimatas" General Hospital, 11527 Athens, Greece
| | - Marianna Tzanoudaki
- Department of Immunology, "Aghia Sophia" Children's Hospital, 11527 Athens, Greece
| | - Vassilios Papadakis
- Department of Pediatric Hematology-Oncology (TAO), "Aghia Sophia" Children's Hospital, 11527 Athens, Greece
| | - Lina Florentin
- Alfa Laboratory Diagnostic Center, YGEIA Hospital, 11524 Athens, Greece
| | - Sophia Polychronopoulou
- Department of Pediatric Hematology-Oncology (TAO), "Aghia Sophia" Children's Hospital, 11527 Athens, Greece
| |
Collapse
|
3
|
Kotsidi M, Gorgolis G, Pastore Carbone MG, Paterakis G, Anagnostopoulos G, Trakakis G, Manikas AC, Pavlou C, Koutroumanis N, Galiotis C. Graphene nanoplatelets and other 2D-materials as protective means against the fading of coloured inks, dyes and paints. Nanoscale 2023; 15:5414-5428. [PMID: 36826806 PMCID: PMC10019573 DOI: 10.1039/d2nr05795f] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Grants] [Track Full Text] [Figures] [Subscribe] [Scholar Register] [Received: 10/18/2022] [Accepted: 02/17/2023] [Indexed: 06/18/2023]
Abstract
The present work demonstrates the ability of graphene nanoplatelets (GNPs) and other two-dimensional materials (2DMs) like tungsten disulfide (WS2), molybdenum disulfide (MoS2) and hexagonal boron nitride (hBN) to act as protective barriers against the fading of architectural paints and also inks/paints used in art. The results present a new approach for improving the lightfastness of colours of artworks and painted indoor/outdoor wall surfaces taking advantage of the remarkable properties of 2DMs. As shown herein, commercial inks and architectural paints of different colours doped with graphene nanoplatelets (GNPs), graphene oxide (GO), reduced graphene oxide (rGO) and other 2DMs, exhibit a superior resistance to fading under ultraviolet radiation or even under exposure to visible light. A spectroscopic study on these inks and dyes reveals that the peaks which are characteristic of the colour pigments are less affected from aging/fading when the GNPs and the other 2DMs are present. The protection mechanism for the GNPs and the other 2DMs differs. For GNPs, mainly their high surface area which leads to free radicals scavenging (especially hydroxyl radicals), and secondarily their UV absorption, are responsible for their protection effects, while for GO, a transition to rGO structures and consequently to 'smart' paints can be observed after the performed aging routes. In this way, the paint gets improved by time preventing or slowing its own fading and decolorization. For the other 2DMs, the transition-metal dichalcogenides performed better than hBN, even though they all absorb in the UV region. This can be ascribed to the facts that the formers also absorb in the visible, while hBN does not, while most importantly, they can trap reactive oxygen species (ROS) and corrosive gases in their structure as opposed to hBN. By conducting colorimetric measurements, we have discovered that the lifetime of the as-developed 2DM-doped inks and paints can be extended by up to ∼40%.
Collapse
Affiliation(s)
- M Kotsidi
- Institute of Chemical Engineering Sciences, Foundation for Research and Technology - Hellas (FORTH/ICE-HT), Patras 265 04, Greece.
- Department of Chemical Engineering, University of Patras, Patras 26504, Greece
| | - G Gorgolis
- Institute of Chemical Engineering Sciences, Foundation for Research and Technology - Hellas (FORTH/ICE-HT), Patras 265 04, Greece.
- Department of Chemical Engineering, University of Patras, Patras 26504, Greece
| | - M G Pastore Carbone
- Institute of Chemical Engineering Sciences, Foundation for Research and Technology - Hellas (FORTH/ICE-HT), Patras 265 04, Greece.
| | - G Paterakis
- Institute of Chemical Engineering Sciences, Foundation for Research and Technology - Hellas (FORTH/ICE-HT), Patras 265 04, Greece.
| | - G Anagnostopoulos
- Institute of Chemical Engineering Sciences, Foundation for Research and Technology - Hellas (FORTH/ICE-HT), Patras 265 04, Greece.
| | - G Trakakis
- Institute of Chemical Engineering Sciences, Foundation for Research and Technology - Hellas (FORTH/ICE-HT), Patras 265 04, Greece.
| | - A C Manikas
- Department of Chemical Engineering, University of Patras, Patras 26504, Greece
| | - C Pavlou
- Institute of Chemical Engineering Sciences, Foundation for Research and Technology - Hellas (FORTH/ICE-HT), Patras 265 04, Greece.
| | - N Koutroumanis
- Institute of Chemical Engineering Sciences, Foundation for Research and Technology - Hellas (FORTH/ICE-HT), Patras 265 04, Greece.
| | - C Galiotis
- Institute of Chemical Engineering Sciences, Foundation for Research and Technology - Hellas (FORTH/ICE-HT), Patras 265 04, Greece.
- Department of Chemical Engineering, University of Patras, Patras 26504, Greece
| |
Collapse
|
4
|
Tsagarakis NJ, Androutsos G, Chaliori I, Chaniotaki S, Paterakis G, Kritikou‐Griva E. Intracytoplasmic crystalline inclusions in blasts of acute myeloid leukaemia with myelodysplasia‐related changes (
AML‐MRC
). Int J Lab Hematol 2022; 44:1027-1028. [DOI: 10.1111/ijlh.13968] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/18/2022] [Accepted: 08/26/2022] [Indexed: 11/29/2022]
Affiliation(s)
| | - Georgios Androutsos
- Hematology Laboratory General Hospital of Athens "G. Gennimatas" Athens Greece
| | - Ioulia Chaliori
- Hematology Laboratory General Hospital of Athens "G. Gennimatas" Athens Greece
| | - Sofia Chaniotaki
- Hematology Laboratory General Hospital of Athens "G. Gennimatas" Athens Greece
| | - Georgios Paterakis
- Hematology Laboratory General Hospital of Athens "G. Gennimatas" Athens Greece
| | | |
Collapse
|
5
|
Maurer-Granofszky M, Schumich A, Buldini B, Gaipa G, Kappelmayer J, Mejstrikova E, Karawajew L, Rossi J, Suzan AÇ, Agriello E, Anastasiou-Grenzelia T, Barcala V, Barna G, Batinić D, Bourquin JP, Brüggemann M, Bukowska-Strakova K, Burnusuzov H, Carelli D, Deniz G, Dubravčić K, Feuerstein T, Gaillard MI, Galeano A, Giordano H, Gonzalez A, Groeneveld-Krentz S, Hevessy Z, Hrusak O, Iarossi MB, Jáksó P, Kloboves Prevodnik V, Kohlscheen S, Kreminska E, Maglia O, Malusardi C, Marinov N, Martin BM, Möller C, Nikulshin S, Palazzi J, Paterakis G, Popov A, Ratei R, Rodríguez C, Sajaroff EO, Sala S, Samardzija G, Sartor M, Scarparo P, Sędek Ł, Slavkovic B, Solari L, Svec P, Szczepanski T, Taparkou A, Torrebadell M, Tzanoudaki M, Varotto E, Vernitsky H, Attarbaschi A, Schrappe M, Conter V, Biondi A, Felice M, Campbell M, Kiss C, Basso G, Dworzak MN. An Extensive Quality Control and Quality Assurance (QC/QA) Program Significantly Improves Inter-Laboratory Concordance Rates of Flow-Cytometric Minimal Residual Disease Assessment in Acute Lymphoblastic Leukemia: An I-BFM-FLOW-Network Report. Cancers (Basel) 2021; 13:cancers13236148. [PMID: 34885257 PMCID: PMC8656726 DOI: 10.3390/cancers13236148] [Citation(s) in RCA: 14] [Impact Index Per Article: 4.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/30/2021] [Revised: 11/25/2021] [Accepted: 11/30/2021] [Indexed: 11/30/2022] Open
Abstract
Simple Summary Standardization of flow-cytometric assessment of minimal residual disease in acute lymphoid leukemia (ALL) is necessary to allow concordant multicentric application of the methodology. This is a prerequisite for internationally collaborative trials, such as the AIEOP-BFM-ALL and the ALL IC-BFM trial. We developed and applied a comprehensive training and quality control program involving a large number of international laboratories within the I-BFM consortium to complement standardization of the methodology with an educational component as well as with persistent quality control measures to allow large ALL treatment trials which use multi-laboratory FCM-MRD assessments for risk stratification of pediatric patients with ALL. Abstract Monitoring of minimal residual disease (MRD) by flow cytometry (FCM) is a powerful prognostic tool for predicting outcomes in acute lymphoblastic leukemia (ALL). To apply FCM-MRD in large, collaborative trials, dedicated laboratory staff must be educated to concordantly high levels of expertise and their performance quality should be continuously monitored. We sought to install a unique and comprehensive training and quality control (QC) program involving a large number of reference laboratories within the international Berlin-Frankfurt-Münster (I-BFM) consortium, in order to complement the standardization of the methodology with an educational component and persistent quality control measures. Our QC and quality assurance (QA) program is based on four major cornerstones: (i) a twinning maturation program, (ii) obligatory participation in external QA programs (spiked sample send around, United Kingdom National External Quality Assessment Service (UK NEQAS)), (iii) regular participation in list-mode-data (LMD) file ring trials (FCM data file send arounds), and (iv) surveys of independent data derived from trial results. We demonstrate that the training of laboratories using experienced twinning partners, along with continuous educational feedback significantly improves the performance of laboratories in detecting and quantifying MRD in pediatric ALL patients. Overall, our extensive education and quality control program improved inter-laboratory concordance rates of FCM-MRD assessments and ultimately led to a very high conformity of risk estimates in independent patient cohorts.
Collapse
Affiliation(s)
| | - Angela Schumich
- Children’s Cancer Research Institute, Medical University of Vienna, 1090 Vienna, Austria; (M.M.-G.); (A.S.)
| | - Barbara Buldini
- Pediatric Hematology, Oncology and Stem Cell Transplant Division, Maternal and Child Health Department, University of Padova, 35122 Padova, Italy; (B.B.); (P.S.); (E.V.); (G.B.)
| | - Giuseppe Gaipa
- M. Tettamanti Foundation Research Center, Department of Pediatrics, University of Milano-Bicocca, 20900 Monza, Italy; (G.G.); (O.M.); (S.S.)
| | - Janos Kappelmayer
- Department of Laboratory Medicine, University of Debrecen, 4032 Debrecen, Hungary; (J.K.); (Z.H.)
| | - Ester Mejstrikova
- Department of Paediatric Haematology and Oncology, University Hospital Motol, 150 06 Prague, Czech Republic; (E.M.); (O.H.)
| | - Leonid Karawajew
- Department of Pediatric Oncology and Hematology, Charité Berlin, 10117 Berlin, Germany; (L.K.); (S.G.-K.)
| | - Jorge Rossi
- Cellular Immunology Laboratory, Hospital de Pediatria “Dr. Juan P. Garrahan”, Buenos Aires C1245, Argentina; (J.R.); (E.O.S.)
| | - Adın Çınar Suzan
- Department of Immunology, Aziz Sancar Institute of Experimental Medicine, Istanbul University, 34452 Istanbul, Turkey; (A.Ç.S.); (G.D.)
| | - Evangelina Agriello
- LEB Laboratorio, Servicio de Hematologia Hospital Penna, Bahia Blanca B8000, Argentina;
| | | | - Virna Barcala
- Laboratory—Flow Cytometry, Citomlab, Buenos Aires C1406AWK, Argentina;
| | - Gábor Barna
- 1st Department of Pathology and Experimental Cancer Research, Semmelweis University, 1085 Budapest, Hungary;
| | - Drago Batinić
- Division of Laboratory Immunology, Department of Laboratory Diagnostics, University Hospital Centre Zagreb & School of Medicine, 10000 Zagreb, Croatia; (D.B.); (K.D.)
| | - Jean-Pierre Bourquin
- Department of Oncology and Children’s Cancer Research Center, University Children’s Hospital, 8032 Zurich, Switzerland; (J.-P.B.); (C.M.)
| | - Monika Brüggemann
- Department of Hematology, University Hospital Schleswig-Holstein, 24105 Kiel, Germany; (M.B.); (S.K.)
| | - Karolina Bukowska-Strakova
- Department of Clinical Immunology, Institute of Pediatrics, Jagiellonian University Medical College, 31-008 Krakow, Poland;
| | - Hasan Burnusuzov
- Center of Competence “PERIMED”, Department of Pediatrics, Department of Microbiology and Clinical Immunology, Medical University Plovdiv, 4002 Plovdiv, Bulgaria;
| | | | - Günnur Deniz
- Department of Immunology, Aziz Sancar Institute of Experimental Medicine, Istanbul University, 34452 Istanbul, Turkey; (A.Ç.S.); (G.D.)
| | - Klara Dubravčić
- Division of Laboratory Immunology, Department of Laboratory Diagnostics, University Hospital Centre Zagreb & School of Medicine, 10000 Zagreb, Croatia; (D.B.); (K.D.)
| | - Tamar Feuerstein
- The Rina Zaizov Division of Pediatric Hematology-Oncology, Schneider’s Children’s Medical Center, Petah Tikva 4920235, Israel;
| | - Marie Isabel Gaillard
- Bioquimica, Inmunologia, Hospital de Ninos Rocardo Gutierrez, Buenos Aires C1425EFD, Argentina;
| | - Adriana Galeano
- Flow Cytometry Laboratory, FUNDALEU, Buenos Aires C1114, Argentina;
| | - Hugo Giordano
- Fundación Pérez Scremini, Pediatric Hematology-Oncology Service, Pereira Rossell Hospital, Montevideo 11600, Uruguay;
| | | | - Stefanie Groeneveld-Krentz
- Department of Pediatric Oncology and Hematology, Charité Berlin, 10117 Berlin, Germany; (L.K.); (S.G.-K.)
| | - Zsuzsanna Hevessy
- Department of Laboratory Medicine, University of Debrecen, 4032 Debrecen, Hungary; (J.K.); (Z.H.)
| | - Ondrej Hrusak
- Department of Paediatric Haematology and Oncology, University Hospital Motol, 150 06 Prague, Czech Republic; (E.M.); (O.H.)
| | - Maria Belen Iarossi
- Flow Cytometry Laboratory, Provincial Histocompatibility Reference Centre, CUCAIBA, Buenos Aires C1114, Argentina;
| | - Pál Jáksó
- Flow Cytometry Laboratory, Department of Pathology, Clinical Centre, University of Pécs, 7622 Pécs, Hungary;
| | - Veronika Kloboves Prevodnik
- Department of Cytopathology, Institute of Oncology, 1000 Ljubljana, Slovenia;
- Faculty of Medicine, University of Ljubljana, 1000 Ljubljana, Slovenia
| | - Saskia Kohlscheen
- Department of Hematology, University Hospital Schleswig-Holstein, 24105 Kiel, Germany; (M.B.); (S.K.)
| | - Elena Kreminska
- Clinical Laboratory Diagnostics and Metrology of NCSH “OHMATDYT”, Ministry of Heath of Ukraine, 01601 Kiev, Ukraine;
| | - Oscar Maglia
- M. Tettamanti Foundation Research Center, Department of Pediatrics, University of Milano-Bicocca, 20900 Monza, Italy; (G.G.); (O.M.); (S.S.)
| | - Cecilia Malusardi
- Hospital de Clinica Jose de San Martin, Buenos Aires C1120, Argentina;
| | - Neda Marinov
- PINDA, Chilean National Pediatric Oncology Group, Hospital Roberto del Rio, Universidad de Chile, Santiago 8380418, Chile; (N.M.); (M.C.)
| | | | - Claudia Möller
- Department of Oncology and Children’s Cancer Research Center, University Children’s Hospital, 8032 Zurich, Switzerland; (J.-P.B.); (C.M.)
| | - Sergey Nikulshin
- Hematopathology and Flow Cytometry Division, Children’s Clinical University Hospital, LV-1004 Riga, Latvia;
| | | | | | - Alexander Popov
- Laboratory of Leukemia Immunophenotyping, Dmitry Rogachev National Medical Research Center of Pediatric Hematology, Oncology and Immunology, 117997 Moscow, Russia;
| | - Richard Ratei
- Clinic for Hematology and Tumor Immunology, HELIOS Klinikum Berlin-Buch, 13125 Berlin, Germany;
| | - Cecilia Rodríguez
- Hospital Nacional de Clínicas, Universidad Nacional de Córdoba, Cordoba X5000HUA, Argentina;
| | - Elisa Olga Sajaroff
- Cellular Immunology Laboratory, Hospital de Pediatria “Dr. Juan P. Garrahan”, Buenos Aires C1245, Argentina; (J.R.); (E.O.S.)
| | - Simona Sala
- M. Tettamanti Foundation Research Center, Department of Pediatrics, University of Milano-Bicocca, 20900 Monza, Italy; (G.G.); (O.M.); (S.S.)
| | - Gordana Samardzija
- Laboratory for Flow Cytometry and Immunology, Institute for Health and Protection of Mother and Child of Serbia, 11070 Belgrade, Serbia; (G.S.); (B.S.)
| | - Mary Sartor
- The Children’s Hospital at Westmead, Sydney, NSW 2145, Australia;
| | - Pamela Scarparo
- Pediatric Hematology, Oncology and Stem Cell Transplant Division, Maternal and Child Health Department, University of Padova, 35122 Padova, Italy; (B.B.); (P.S.); (E.V.); (G.B.)
| | - Łukasz Sędek
- Department of Microbiology and Immunology, Medical University of Silesia, 40-055 Katowice, Poland;
| | - Bojana Slavkovic
- Laboratory for Flow Cytometry and Immunology, Institute for Health and Protection of Mother and Child of Serbia, 11070 Belgrade, Serbia; (G.S.); (B.S.)
| | - Liliana Solari
- Servicio de Bioquimica, Hospital Posadas, Buenos Aires B1684, Argentina;
| | - Peter Svec
- National Institute of Children’s Diseases, 831 01 Bratislava, Slovakia;
| | - Tomasz Szczepanski
- Department of Pediatric Hematology and Oncology, Zabrze, Medical University of Silesia, 40-055 Katowice, Poland;
| | - Anna Taparkou
- Department of Pediatric Oncology Hippokration General Hospital, 546 42 Thessaloniki, Greece;
| | | | - Marianna Tzanoudaki
- Department of Immunology & Histocompatibility, “Agia Sophia” Children’s Hospital, 115 27 Athens, Greece;
| | - Elena Varotto
- Pediatric Hematology, Oncology and Stem Cell Transplant Division, Maternal and Child Health Department, University of Padova, 35122 Padova, Italy; (B.B.); (P.S.); (E.V.); (G.B.)
| | - Helly Vernitsky
- Hematology Lab, Sheba Medical Center, Ramat Gan 52621, Israel;
| | - Andishe Attarbaschi
- St. Anna Children’s Hospital, Department of Pediatrics, Medical University of Vienna, 1090 Vienna, Austria;
| | - Martin Schrappe
- Department of Pediatrics, University Medical Center SchleswigHolstein, Christian-Albrechts-University of Kiel, 24118 Kiel, Germany;
| | - Valentino Conter
- Clinica Pediatrica University degli Studi di Milano Biococca, Fondazione MBBM, 20900 Monza, Italy; (V.C.); (A.B.)
| | - Andrea Biondi
- Clinica Pediatrica University degli Studi di Milano Biococca, Fondazione MBBM, 20900 Monza, Italy; (V.C.); (A.B.)
| | - Marisa Felice
- Department of Hematology and Oncology, Hospital de Pediatria “Dr. Juan P. Garrahan”, Buenos Aires C1245, Argentina;
| | - Myriam Campbell
- PINDA, Chilean National Pediatric Oncology Group, Hospital Roberto del Rio, Universidad de Chile, Santiago 8380418, Chile; (N.M.); (M.C.)
| | - Csongor Kiss
- Division of Pediatric Hematology-Oncology, Department of Pediatrics, Faculty of Medicine, University of Debrecen, 4032 Debrecen, Hungary;
| | - Giuseppe Basso
- Pediatric Hematology, Oncology and Stem Cell Transplant Division, Maternal and Child Health Department, University of Padova, 35122 Padova, Italy; (B.B.); (P.S.); (E.V.); (G.B.)
| | - Michael N. Dworzak
- Children’s Cancer Research Institute, Medical University of Vienna, 1090 Vienna, Austria; (M.M.-G.); (A.S.)
- St. Anna Children’s Hospital, Department of Pediatrics, Medical University of Vienna, 1090 Vienna, Austria;
- Correspondence: ; Tel.: +43-1-40470-4064
| | | |
Collapse
|
6
|
Kritikou-Griva E, Chaliori I, Tsagarakis NJ, Androutsos G, Chaniotaki S, Paterakis G. Green-blue intracytoplasmic inclusions in the bone marrow in severe COVID-19. Blood Res 2021; 56:126. [PMID: 34349042 PMCID: PMC8478625 DOI: 10.5045/br.2021.2021077] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/15/2021] [Revised: 04/27/2021] [Accepted: 07/08/2021] [Indexed: 11/30/2022] Open
Affiliation(s)
- Elpiniki Kritikou-Griva
- Department of Laboratory Hematology, General Hospital of Athens "G. Gennimatas," Athens, Greece
| | - Ioulia Chaliori
- Department of Laboratory Hematology, General Hospital of Athens "G. Gennimatas," Athens, Greece
| | - Nikolaos J Tsagarakis
- Department of Laboratory Hematology, General Hospital of Athens "G. Gennimatas," Athens, Greece
| | - Georgios Androutsos
- Department of Laboratory Hematology, General Hospital of Athens "G. Gennimatas," Athens, Greece
| | - Sofia Chaniotaki
- Department of Laboratory Hematology, General Hospital of Athens "G. Gennimatas," Athens, Greece
| | - Georgios Paterakis
- Department of Laboratory Hematology, General Hospital of Athens "G. Gennimatas," Athens, Greece
| |
Collapse
|
7
|
Kotsidi M, Gorgolis G, Pastore Carbone MG, Anagnostopoulos G, Paterakis G, Poggi G, Manikas A, Trakakis G, Baglioni P, Galiotis C. Preventing colour fading in artworks with graphene veils. Nat Nanotechnol 2021; 16:1004-1010. [PMID: 34211165 DOI: 10.1038/s41565-021-00934-z] [Citation(s) in RCA: 11] [Impact Index Per Article: 3.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Subscribe] [Scholar Register] [Received: 12/11/2019] [Accepted: 05/20/2021] [Indexed: 06/13/2023]
Abstract
Modern and contemporary art materials are generally prone to irreversible colour changes upon exposure to light and oxidizing agents. Graphene can be produced in thin large sheets, blocks ultraviolet light, and is impermeable to oxygen, moisture and corrosive agents; therefore, it has the potential to be used as a transparent layer for the protection of art objects in museums, during storage and transportation. Here we show that a single-layer or multilayer graphene veil, produced by chemical vapour deposition, can be deposited over artworks to protect them efficiently against colour fading, with a protection factor of up to 70%. We also show that this process is reversible since the graphene protective layer can be removed using a soft rubber eraser without causing any damage to the artwork. We have also explored a complementary contactless graphene-based route for colour protection that is based on the deposition of graphene on picture framing glass for use when the direct application of graphene is not feasible due to surface roughness or artwork fragility. Overall, the present results are a proof of concept of the potential use of graphene as an effective and removable protective advanced material to prevent colour fading in artworks.
Collapse
Affiliation(s)
- M Kotsidi
- Institute of Chemical Engineering Sciences, Foundation for Research and Technology - Hellas (FORTH/ ICE-HT), Patras, Greece
- Department of Chemical Engineering, University of Patras, Patras, Greece
| | - G Gorgolis
- Institute of Chemical Engineering Sciences, Foundation for Research and Technology - Hellas (FORTH/ ICE-HT), Patras, Greece
| | - M G Pastore Carbone
- Institute of Chemical Engineering Sciences, Foundation for Research and Technology - Hellas (FORTH/ ICE-HT), Patras, Greece
| | - G Anagnostopoulos
- Institute of Chemical Engineering Sciences, Foundation for Research and Technology - Hellas (FORTH/ ICE-HT), Patras, Greece
| | - G Paterakis
- Institute of Chemical Engineering Sciences, Foundation for Research and Technology - Hellas (FORTH/ ICE-HT), Patras, Greece
- Department of Chemical Engineering, University of Patras, Patras, Greece
| | - G Poggi
- CSGI & Department of Chemistry, University of Florence, Sesto Fiorentino, Italy
| | - A Manikas
- Department of Chemical Engineering, University of Patras, Patras, Greece
| | - G Trakakis
- Institute of Chemical Engineering Sciences, Foundation for Research and Technology - Hellas (FORTH/ ICE-HT), Patras, Greece
| | - P Baglioni
- CSGI & Department of Chemistry, University of Florence, Sesto Fiorentino, Italy
| | - C Galiotis
- Institute of Chemical Engineering Sciences, Foundation for Research and Technology - Hellas (FORTH/ ICE-HT), Patras, Greece.
- Department of Chemical Engineering, University of Patras, Patras, Greece.
| |
Collapse
|
8
|
Ampatzidou M, Florentin L, Papadakis V, Paterakis G, Tzanoudaki M, Bouzarelou D, Papadhimitriou SI, Polychronopoulou S. Copy Number Alteration Profile Provides Additional Prognostic Value for Acute Lymphoblastic Leukemia Patients Treated on BFM Protocols. Cancers (Basel) 2021; 13:cancers13133289. [PMID: 34209196 PMCID: PMC8268490 DOI: 10.3390/cancers13133289] [Citation(s) in RCA: 7] [Impact Index Per Article: 2.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/10/2021] [Revised: 06/25/2021] [Accepted: 06/25/2021] [Indexed: 01/03/2023] Open
Abstract
Simple Summary Recent advances in genomic analyses of acute lymphoblastic leukemia (ALL) have identified novel prognostic markers associated with patient outcome. In this frame, copy number alterations (CNAs) are constantly gaining relevance as potential risk stratification markers. Herein, we present our data of a proposed CNA-profile risk-index applied on a Greek ALLIC-BFM cohort. The results of our study demonstrate that EFS for GR(good-risk)-CNA-profile patients was 96.0% versus 57.6% of PR(poor-risk)-CNA-profile ones (p < 0.001) in the whole cohort. EFS within the IR-group for the GR-CNA vs. PR-CNA subgroups was 100.0% vs. 60.0% (p < 0.001), and within the HR-group, 88.2% vs. 55.6% (p = 0.047), respectively. The above results indicate that the application of the proposed CNA-profile classifier is feasible in BFM-based protocols, adding prognostic value to the existing prognostic markers and successfully stratifying patients within prognostic subgroups. This novel genomic risk index can be incorporated in future risk-stratification algorithms, further refining MRD-based stratification and possibly reassigning optimal treatment strategies. Abstract We present our data of a novel proposed CNA-profile risk-index, applied on a Greek ALLIC-BFM-treated cohort, aiming at further refining genomic risk-stratification. Eighty-five of 227 consecutively treated ALL patients were analyzed for the copy-number-status of eight genes (IKZF1/CDKN2A/2B/PAR1/BTG1/EBF1/PAX5/ETV6/RB1). Using the MLPA-assay, patients were stratified as: (1) Good-risk(GR)-CNA-profile (n = 51), with no deletion of IKZF1/CDKN2A/B/PAR1/BTG1/EBF1/PAX5/ETV6/RB1 or isolated deletions of ETV6/PAX5/BTG1 or ETV6 deletions with a single additional deletion of BTG1/PAX5/CDKN2A/B. (2) Poor-risk(PR)-CNA-profile (n = 34), with any deletion of ΙΚΖF1/PAR1/EBF1/RB1 or any other CNA. With a median follow-up time of 49.9 months, EFS for GR-CNA-profile and PR-CNA-profile patients was 96.0% vs. 57.6% (p < 0.001). For IR-group and HR-group patients, EFS for the GR-CNA/PR-CNA subgroups was 100.0% vs. 60.0% (p < 0.001) and 88.2% vs. 55.6% (p = 0.047), respectively. Among FC-MRDd15 + patients (MRDd15 ≥ 10−4), EFS rates were 95.3% vs. 51.7% for GR-CNA/PR-CNA subjects (p < 0.001). Similarly, among FC-MRDd33 + patients (MRDd33 ≥ 10−4), EFS was 92.9% vs. 27.3% (p < 0.001) and for patients FC-MRDd33 − (MRDd33 < 10−4), EFS was 97.2% vs. 72.7% (p = 0.004), for GR-CNA/PR-CNA patients, respectively. In a multivariate analysis, the CNA-profile was the most important outcome predictor. In conclusion, the CNA-profile can establish a new genomic risk-index, identifying a distinct subgroup with increased relapse risk among the IR-group, as well as a subgroup of patients with superior prognosis among HR-patients. The CNA-profile is feasible in BFM-based protocols, further refining MRD-based risk-stratification.
Collapse
Affiliation(s)
- Mirella Ampatzidou
- Department of Pediatric Hematology-Oncology, “Aghia Sophia” Children’s Hospital, 11527 Athens, Greece; (V.P.); (S.P.)
- Correspondence:
| | - Lina Florentin
- Alfa Laboratory Diagnostic Center, YGEIA Hospital, 11524 Athens, Greece; (L.F.); (D.B.)
| | - Vassilios Papadakis
- Department of Pediatric Hematology-Oncology, “Aghia Sophia” Children’s Hospital, 11527 Athens, Greece; (V.P.); (S.P.)
| | - Georgios Paterakis
- Laboratory of Flow Cytometry, Department of Immunology, “G.Gennimatas” General Hospital, 11527 Athens, Greece;
| | - Marianna Tzanoudaki
- Department of Immunology, “Aghia Sophia” Children’s Hospital, 11527 Athens, Greece;
| | - Dimitra Bouzarelou
- Alfa Laboratory Diagnostic Center, YGEIA Hospital, 11524 Athens, Greece; (L.F.); (D.B.)
| | - Stefanos I. Papadhimitriou
- Laboratory of Hematology, Department of Molecular Cytogenetics, “G.Gennimatas” General Hospital, 11527 Athens, Greece;
| | - Sophia Polychronopoulou
- Department of Pediatric Hematology-Oncology, “Aghia Sophia” Children’s Hospital, 11527 Athens, Greece; (V.P.); (S.P.)
| |
Collapse
|
9
|
Tsikandilakis M, Leong MQ, Yu Z, Paterakis G, Bali P, Derrfuss J, Mevel PA, Milbank A, Tong EMW, Madan C, Mitchell P. "Speak of the Devil… and he Shall Appear": Religiosity, Unconsciousness, and the Effects of Explicit Priming in the Misperception of Immorality. Psychol Res 2021; 86:37-65. [PMID: 33484351 DOI: 10.1007/s00426-020-01461-7] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/06/2020] [Accepted: 12/07/2020] [Indexed: 10/22/2022]
Abstract
Psychological theory and research suggest that religious individuals could have differences in the appraisal of immoral behaviours and cognitions compared to non-religious individuals. This effect could occur due to adherence to prescriptive and inviolate deontic religious-moral rules and socio-evolutionary factors, such as increased autonomic nervous system responsivity to indirect threat. The latter thesis has been used to suggest that immoral elicitors could be processed subliminally by religious individuals. In this manuscript, we employed masking to test this hypothesis. We rated and pre-selected IAPS images for moral impropriety. We presented these images masked with and without negatively manipulating a pre-image moral label. We measured detection, moral appraisal and discrimination, and physiological responses. We found that religious individuals experienced higher responsivity to masked immoral images. Bayesian and hit-versus-miss response analyses revealed that the differences in appraisal and physiological responses were reported only for consciously perceived immoral images. Our analysis showed that when a negative moral label was presented, religious individuals experienced the interval following the label as more physiologically arousing and responded with lower specificity for moral discrimination. We propose that religiosity involves higher conscious perceptual and physiological responsivity for discerning moral impropriety but also higher susceptibility for the misperception of immorality.
Collapse
Affiliation(s)
- Myron Tsikandilakis
- School of Psychology, University of Nottingham, Nottingham, UK.
- Medical School, Faculty of Medicine and Health Sciences, University of Nottingham, Nottingham, UK.
| | - Man Qing Leong
- Department of Psychology, National University of Singapore, Singapore, Singapore
| | - Zhaoliang Yu
- Department of Psychology, National University of Singapore, Singapore, Singapore.
| | | | - Persefoni Bali
- School of Psychology, University of Nottingham, Nottingham, UK
| | - Jan Derrfuss
- School of Psychology, University of Nottingham, Nottingham, UK
| | - Pierre-Alexis Mevel
- Department of Modern Languages and Cultures, University of Nottingham, Nottingham, UK
| | - Alison Milbank
- Department of Theology and Religious Studies, University of Nottingham, Nottingham, UK
| | - Eddie M W Tong
- Department of Psychology, National University of Singapore, Singapore, Singapore
| | | | - Peter Mitchell
- School of Psychology, University of Nottingham, Nottingham, UK
| |
Collapse
|
10
|
Ampatzidou M, Kattamis A, Baka M, Paterakis G, Anastasiou T, Tzanoudaki M, Kaisari A, Avgerinou G, Doganis D, Papadakis V, Kitra V, Polychronopoulou S. Insights from the Greek experience of the use of Blinatumomab in pediatric relapsed and refractory acute lymphoblastic leukemia patients. Neoplasma 2020; 67:1424-1430. [PMID: 32701357 DOI: 10.4149/neo_2020_200128n93] [Citation(s) in RCA: 13] [Impact Index Per Article: 3.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/28/2020] [Accepted: 04/29/2020] [Indexed: 11/08/2022]
Abstract
Pediatric refractory or relapsed acute lymphoblastic leukemia (ALL) poses unique therapeutic challenges, with novel immunotherapy approaches offering potential cure opportunities. In this frame, the use of Blinatumomab may induce durable remissions, serving as a successful bridge to allogeneic hematopoietic stem cell transplantation (allo-HSCT). Herein, we retrospectively summarize the Greek experience on pediatric relapsed/refractory B-cell precursor ALL patients that were treated with Blinatumomab in a compassionate, off-label setting as an effort to achieve disease clearance and proceed to allo-HSCT. In our cohort of 9 patients, 6/9 (66.7%) responded to Blinatumomab, achieving complete morphological remission (CR) after the 1st cycle, while minimal/measurable residual disease (MRD)-negativity (<10-4) after the 1st cycle was achieved in 2/2 patients (100.0%) with prior CR. A successful bridge to HSCT was feasible in 5/9 patients (55.6%). Median relapse-free survival (RFS) was 3.0 months (range 0.5-21.4 months) and median overall survival (OS) was 8.7 months (range 1.4-47.1 months) for the whole pediatric cohort. There was a trend of prolonged survival among patients who achieved MRD response after the 1st Blinatumomab administration. MRD response (defined as the >=2-log reduction of MRD value before and after Blinatumomab administration), was associated with a median RFS/OS of 7.4/7.6 months, while lack of MRD response was associated with a median RFS/OS of 0.5/3.0 months, respectively. Novel therapeutic maneuvers, in order to overcome disease resistance, i.e. increased usage of Blinatumomab dose (45 μg/m2/day), combination with donor lymphocyte infusions (DLIs), use of other immunotherapy salvage approaches (inotuzumabozogamicin), are herein discussed. Additionally, the optimal number of Blinatumomab cycles, the CD19-negative relapses and lineage switch, are also addressed. Our data although referred to a limited, however refractory or relapsed and heavily pretreated number of patients, strongly suggest that Blinatumomab may well induce sustained remissions and serve as an effective bridge to HSCT. Whether immunotherapy combined with chemotherapy can outweigh the need for subsequent allo-HSCT, if incorporated into frontline high-risk ALL therapy, remains an optimistic issue to be verified in future randomized clinical trials.
Collapse
Affiliation(s)
- M Ampatzidou
- Department of Pediatric Hematology-Oncology, Aghia Sophia Children's Hospital, Athens, Greece
| | - A Kattamis
- First Department of Pediatrics, Aghia Sophia Children's Hospital, National and Kapodistrian University of Athens, Athens, Greece
| | - M Baka
- Oncology Department, P. and A. Kyriakou Children's Hospital, Athens, Greece
| | - G Paterakis
- Immunology Laboratory, Department of Flow Cytometry , G. Gennimatas General Hospital, Athens, Greece
| | - T Anastasiou
- Hematology Laboratory, P. and A. Kyriakou Children's Hospital, Athens, Greece
| | - M Tzanoudaki
- Immunology Laboratory, Aghia Sophia Children's Hospital, Athens, Greece
| | - A Kaisari
- Bone Marrow Transplantation Unit, Aghia Sophia Children's Hospital, Athens, Greece
| | - G Avgerinou
- First Department of Pediatrics, Aghia Sophia Children's Hospital, National and Kapodistrian University of Athens, Athens, Greece
| | - D Doganis
- Oncology Department, P. and A. Kyriakou Children's Hospital, Athens, Greece
| | - V Papadakis
- Department of Pediatric Hematology-Oncology, Aghia Sophia Children's Hospital, Athens, Greece
| | - V Kitra
- Bone Marrow Transplantation Unit, Aghia Sophia Children's Hospital, Athens, Greece
| | - S Polychronopoulou
- Department of Pediatric Hematology-Oncology, Aghia Sophia Children's Hospital, Athens, Greece
| |
Collapse
|
11
|
Tsagarakis NJ, Papadhimitriou SI, Pavlidis D, Liapis K, Gortzolidis G, Kostopoulos IV, Marinakis T, Paterakis G. Contribution of immunophenotype to the investigation and differential diagnosis of Burkitt lymphoma, double‐hit high‐grade B‐cell lymphoma, and single‐hit
MYC
‐rearranged diffuse large B‐cell lymphoma. Cytometry 2020; 98:412-420. [DOI: 10.1002/cyto.b.21887] [Citation(s) in RCA: 6] [Impact Index Per Article: 1.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Subscribe] [Scholar Register] [Received: 11/15/2019] [Revised: 04/22/2020] [Accepted: 04/23/2020] [Indexed: 11/08/2022]
Affiliation(s)
- Nikolaos J. Tsagarakis
- Department of Laboratory Hematology Athens Regional General Hospital Georgios Gennimatas Athens Greece
| | | | - Dimitris Pavlidis
- Department of Laboratory Hematology Athens Regional General Hospital Georgios Gennimatas Athens Greece
| | - Konstantinos Liapis
- Department of Clinical Hematology Athens Regional General Hospital Georgios Gennimatas Athens Greece
| | - Georgios Gortzolidis
- Department of Clinical Hematology Athens Regional General Hospital Georgios Gennimatas Athens Greece
| | - Ioannis V. Kostopoulos
- Department of Laboratory Hematology Athens Regional General Hospital Georgios Gennimatas Athens Greece
| | - Theodoros Marinakis
- Department of Clinical Hematology Athens Regional General Hospital Georgios Gennimatas Athens Greece
| | - Georgios Paterakis
- Flow Cytometry Laboratory, Department of Immunology Athens Regional General Hospital Georgios Gennimatas Athens Greece
| |
Collapse
|
12
|
Oudatzis G, Tsagarakis NJ, Paterakis G, Vasileiou P, Xenou E, Maraki P, Pangrati T, Angelopoulou MK, Vassilakopoulos TP, Konstantopoulos K. Evaluation of automated capillary complete blood counts for routine clinical decision making in a large cohort of hematological patients, using Mindray BC‐3000 Plus Auto and Sysmex XE‐5000 hematology analyzers. Int J Lab Hematol 2020; 42:565-572. [DOI: 10.1111/ijlh.13237] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/20/2020] [Revised: 04/22/2020] [Accepted: 04/25/2020] [Indexed: 01/21/2023]
Affiliation(s)
- Georgios Oudatzis
- Department of Hematology Athens University School of Medicine at Laikon General Hospital Athens Greece
| | - Nikolaos J. Tsagarakis
- Department of Laboratory Hematology Athens Regional General Hospital "G. Gennimatas" Athens Greece
| | - Georgios Paterakis
- Department of Immunology Athens Regional General Hospital "G. Gennimatas" Athens Greece
| | | | - Efthalia Xenou
- HematologyLaboratoryLaikon General Hospital Athens Greece
| | - Paraskevi Maraki
- Department of Hematology Athens University School of Medicine at Laikon General Hospital Athens Greece
| | - Toula Pangrati
- HematologyLaboratoryLaikon General Hospital Athens Greece
| | - Maria K. Angelopoulou
- Department of Hematology Athens University School of Medicine at Laikon General Hospital Athens Greece
| | | | - Kostas Konstantopoulos
- Department of Hematology Athens University School of Medicine at Laikon General Hospital Athens Greece
| |
Collapse
|
13
|
Abstract
PURPOSE OF REVIEW The purpose of this review was to summarize the clinical, diagnostic, and therapeutic features of blastic plasmacytoid dendritic cell neoplasm (BPDCN). RECENT FINDINGS Several case reports and series revealed new clinical, molecular, diagnostic, and therapeutic aspects of the disease. The clinical presentation diversity has been confirmed, with frequent leukemic non-cutaneous or rare atypical manifestations. The clonal evolution in the development of BPDCN has not been sufficiently elucidated. Although certain immunophenotypic markers (CD4, TCL1, CD123, CD56, CD303) are indicative of BPDCN, the diagnosis remains in certain cases challenging. Adult (ALL)-type chemotherapy followed by hematopoietic stem cell transplantation (HSCT) is related to a favorable outcome, while chemotherapy alone seems enough in children. Future studies should continue to investigate whether CD123-directed therapies could be utilized. BPDCN is a rare aggressive malignancy that needs an aggressive induction therapy. Although a diagnostic consensus is still lacking, and large retrospective studies are also needed to obtain standardized treatment guidelines, the future perspectives are encouraging, because of novel therapeutic agents that are under investigation.
Collapse
Affiliation(s)
- Nikolaos J Tsagarakis
- Department of Immunology, "G. Gennimatas" General Hospital, Mesogion Avenue 154, 11527, Athens, Greece.
| | - Georgios Paterakis
- Department of Immunology, "G. Gennimatas" General Hospital, Mesogion Avenue 154, 11527, Athens, Greece
| |
Collapse
|
14
|
Theodorakos I, Paterakis G, Papadakis V, Vicha A, Topakas G, Jencova P, Karchilaki E, Taparkou A, Tsagarakis NJ, Polychronopoulou S. Interference of bone marrow CD56 + mesenchymal stromal cells in minimal residual disease investigation of neuroblastoma and other CD45 - /CD56 + pediatric malignancies using flow cytometry. Pediatr Blood Cancer 2019; 66:e27799. [PMID: 31066205 DOI: 10.1002/pbc.27799] [Citation(s) in RCA: 8] [Impact Index Per Article: 1.6] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 01/13/2019] [Revised: 04/17/2019] [Accepted: 04/22/2019] [Indexed: 12/15/2022]
Abstract
BACKGROUND Bone marrow (BM) samples obtained from minimal residual disease (MRD)-negative children with B-cell acute lymphoblastic leukemia (B-ALL) were used in our laboratory as negative biological controls for the development of a neuroblastoma (NBL) flow-cytometric (FC) protocol. The accidental, but systematic, identification of rare cell populations (RCP) mimicking NBL cells (CD45- /CD56+ ) in these samples indicated the need for their thorough immunophenotypic identification, in order to elucidate their possible interference in NBL-MRD assessment. PROCEDURE RCP observed in BM samples from 14 children recovering from BM aplasia due to intensive chemotherapy for B-ALL were investigated with the following markers: CD81, CD200, CD24, GD2, CD73, CD13, CD90, CD146, CD9, CD117, CD10, CD99, and NG2. BM samples from six newly diagnosed patients with NBL and an NBL cell line were simultaneously investigated as positive controls. RESULTS The frequency of RCP in B-ALL BM samples was < 1/1 × 104 cells (bulky lysis), and their immunophenotypic profile was indicative of CD56+ mesenchymal stromal cells (MSCs) (CD45- , CD90+ , CD146+ , CD73+ ). Also, RCP expressed CD81 and CD200, simulating NBL cells. The most useful discriminative markers for CD56+ MSCs were CD13 and CD73. An appropriate protocol consisting of two tubes with seven color combinations was further proposed: SYTO-16, GD2 (first tube) or CD73 (second tube)-PE, CD24-ECD, CD13-PC5.5, CD45-PC7, CD81-APC, and CD56-APC700. CONCLUSIONS RCP that were immunophenotypically similar to NBL were identified as CD56+ MSCs. As these cells might pose an obstacle to accurate NBL disease assessment by FC, especially MRD, an enhanced NBL-FC protocol is proposed for prospective evaluation.
Collapse
Affiliation(s)
- Ioannis Theodorakos
- Flow Cytometry Laboratory, Department of Immunology, Athens Regional General Hospital "G. Gennimatas,", Athens, Greece
| | - Georgios Paterakis
- Flow Cytometry Laboratory, Department of Immunology, Athens Regional General Hospital "G. Gennimatas,", Athens, Greece
| | - Vassilios Papadakis
- Department of Pediatric Hematology-Oncology, "Aghia Sophia" Children's Hospital, Athens, Greece
| | - Ales Vicha
- Department of Pediatric Hematology and Oncology, Charles University, 2nd Faculty of Medicine and Faculty Hospital Motol, Prague, Czech Republic
| | - Georgios Topakas
- Flow Cytometry Laboratory, Department of Immunology, Athens Regional General Hospital "G. Gennimatas,", Athens, Greece
| | - Pavla Jencova
- Department of Pediatric Hematology and Oncology, Charles University, 2nd Faculty of Medicine and Faculty Hospital Motol, Prague, Czech Republic
| | - Eirini Karchilaki
- Flow Cytometry Laboratory, Department of Immunology, Athens Regional General Hospital "G. Gennimatas,", Athens, Greece
| | - Anna Taparkou
- 1st Department of Pediatrics, Aristotle University of Thessaloniki, Hippokration Hospital, Thessaloniki, Greece
| | - Nikolaos J Tsagarakis
- Flow Cytometry Laboratory, Department of Immunology, Athens Regional General Hospital "G. Gennimatas,", Athens, Greece
| | - Sophia Polychronopoulou
- Department of Pediatric Hematology-Oncology, "Aghia Sophia" Children's Hospital, Athens, Greece
| |
Collapse
|
15
|
Tsagarakis NJ, Paterakis G, Papadhimitriou SI, Kritikou-Griva E, Goumakou E, Oudatzis G, Theodorakos I, Vasileiou P. "Bone marrow aspirate automated counts on hematology analyzers: formulating a scoring system based on hematology parameters, to discriminate reactive versus myelodysplastic syndrome-related bone marrows". Int J Lab Hematol 2019; 41:542-549. [PMID: 31102331 DOI: 10.1111/ijlh.13049] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/07/2019] [Revised: 04/22/2019] [Accepted: 04/25/2019] [Indexed: 11/30/2022]
Abstract
INTRODUCTION Diagnosis of myelodysplastic syndromes (MDS) is usually challenging. In this context, we have attempted to employ data derived from automated analysis of bone marrow (BM) samples as an ancillary tool for the discrimination between reactive marrow and MDS. METHODS A total of 101 BM anticoagulated samples referred for flow cytometry (FCM) analysis on the clinical suspicion of MDS had been previously counted in a Mindray BC-6800 hematology analyzer (testing set). Among them, 22/101 randomly selected BM samples (comparison set) had been also simultaneously counted by an Advia 2120 and a CELL-DYN Sapphire hematology analyzer. Selected parameters obtained by Mindray BC-6800 were retrospectively evaluated with ROC and regression analysis in an attempt to formulate a discriminative scoring system (SS) for MDS. This system was further evaluated in the comparison set. RESULTS The diagnosis of MDS was established in 37/101 patients assessed ("MDS" group). Three patients were diagnosed with myelodysplastic/myeloproliferative neoplasm (MDS/MPN), while 61 revealed a "reactive" bone marrow ("RBM" group). Statistical analysis revealed significant differences in Hb, RDW-CV%, NRBC%, and RET% values between the "MDS" and the "RBM" group. Specific cutoff values were then indicated and employed for the formulation of a SS of high sensitivity (86.84%) and specificity (86.89%). The encouraging performance characteristics of the proposed SS were also confirmed in the BM comparison set. CONCLUSION Automated BM counts on hematology analyzers contributed to the formulation of a SS for the screening discrimination between reactive and MDS BM fluids, which seems to be applicable and informative, regardless of the analyzer used.
Collapse
Affiliation(s)
- Nikolaos J Tsagarakis
- Department of Laboratory Hematology, Athens Regional General Hospital "G. Gennimatas", Athens, Greece
| | - Georgios Paterakis
- Department of Immunology, Athens Regional General Hospital "G. Gennimatas", Athens, Greece
| | - Stefanos I Papadhimitriou
- Department of Laboratory Hematology, Athens Regional General Hospital "G. Gennimatas", Athens, Greece
| | - Elpiniki Kritikou-Griva
- Department of Laboratory Hematology, Athens Regional General Hospital "G. Gennimatas", Athens, Greece
| | - Eleni Goumakou
- Department of Laboratory Hematology, Athens Regional General Hospital "G. Gennimatas", Athens, Greece
| | | | - Ioannis Theodorakos
- Department of Immunology, Athens Regional General Hospital "G. Gennimatas", Athens, Greece
| | | |
Collapse
|
16
|
Ampatzidou M, Papadhimitriou SI, Paterakis G, Pavlidis D, Tsitsikas Κ, Kostopoulos IV, Papadakis V, Vassilopoulos G, Polychronopoulou S. ETV6/RUNX1-positive childhood acute lymphoblastic leukemia (ALL): The spectrum of clonal heterogeneity and its impact on prognosis. Cancer Genet 2018; 224-225:1-11. [PMID: 29778230 DOI: 10.1016/j.cancergen.2018.03.001] [Citation(s) in RCA: 13] [Impact Index Per Article: 2.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/22/2017] [Revised: 03/14/2018] [Accepted: 03/21/2018] [Indexed: 11/22/2022]
Abstract
The prognostic significance of the ETV6/RUNX1-fusion and of the accompanying aberrations is disputable; whether co-existing sub-clones are responsible for delayed MRD-clearance and thus, moderate outcome, remains to be clarified. We studied, in a paediatric cohort of 119 B-ALLs, the relation between the ETV6/RUNX1 aberration and the co-existing subclones with (a) presenting clinical/biological features, (b) early response to treatment(MRD) and (c) long-term outcome over a 12-year period. Patients were homogeneously treated according to BFM-based-protocols. 27/119 patients (22.7%) were ETV6/RUNX1-positive; 19/27 (70.4%) harbored additional genetic abnormalities while 9/19 (33.3%) presented with clonal heterogeneity. The most common abnormalities were del12p13 (37%), 3-6×21q22 (22.2%), del9p21 (18.5%) and 2-3xETV6/RUNX1 (18.5%). MRDd15-positivity (≥10-3) was detected in 44% of the cohort; the corresponding MRD among patients carrying subclones rises to 88.9%. Common features of all relapses were sub-clonal diversity, FCM-MRDd15-positivity and additional del(9p21) while there were no censored relapses among ETV6/RUNX1-positive patients with sole translocation and absence of additional aberrations, within a median follow-up time of 90 months. In our study, the presence of clonal heterogeneity and impaired FCM-MRD clearance among ETV6/RUNX1-positive patients, ultimately influenced prognosis. Longer follow-up is needed in order to further validate these initial results.
Collapse
Affiliation(s)
- M Ampatzidou
- Department of Pediatric Hematology-Oncology, "Aghia Sophia" Childrens' Hospital, Athens, Greece.
| | - S I Papadhimitriou
- Hematology Laboratory, Department of Molecular Genetics, "G.Gennimatas" General Hospital, Athens, Greece
| | - G Paterakis
- Immunology Laboratory, "G.Gennimatas" General Hospital, Athens, Greece
| | - D Pavlidis
- Hematology Laboratory, Department of Molecular Genetics, "G.Gennimatas" General Hospital, Athens, Greece
| | - Κ Tsitsikas
- Department of Pediatric Hematology-Oncology, "Aghia Sophia" Childrens' Hospital, Athens, Greece
| | - I V Kostopoulos
- Hematology Laboratory, Department of Molecular Genetics, "G.Gennimatas" General Hospital, Athens, Greece
| | - V Papadakis
- Department of Pediatric Hematology-Oncology, "Aghia Sophia" Childrens' Hospital, Athens, Greece
| | - G Vassilopoulos
- Department of Hematology, University Hospital of Larisa, Thessaly Medical School, Larisa, Greece
| | - S Polychronopoulou
- Department of Pediatric Hematology-Oncology, "Aghia Sophia" Childrens' Hospital, Athens, Greece
| |
Collapse
|
17
|
Ampatzidou M, Paterakis G, Vasdekis V, Papadhimitriou SI, Papadakis V, Vassilopoulos G, Polychronopoulou S. Prognostic significance of flow cytometry MRD log reduction during induction treatment of childhood ALL. Leuk Lymphoma 2018; 60:258-261. [PMID: 29963934 DOI: 10.1080/10428194.2018.1471603] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/14/2023]
Affiliation(s)
- Maria Ampatzidou
- a Department of Paediatric Haematology-Oncology , 'Aghia Sophia' Children's Hospital , Athens , Greece
| | - Georgios Paterakis
- b Flow Cytometry Department, Laboratory of Immunology , 'G. Gennimatas' General Hospital , Athens , Greece
| | | | - Stephanos I Papadhimitriou
- d Department of Molecular Cytogenetics, Laboratory of Hematology , 'G. Gennimatas' General Hospital , Athens , Greece
| | - Vassilios Papadakis
- e Department of Hematology , University Hospital of Larisa, Thessaly Medical School , Larisa , Greece
| | - Georgios Vassilopoulos
- e Department of Hematology , University Hospital of Larisa, Thessaly Medical School , Larisa , Greece
| | - Sophia Polychronopoulou
- a Department of Paediatric Haematology-Oncology , 'Aghia Sophia' Children's Hospital , Athens , Greece
| |
Collapse
|
18
|
Nouri E, Wang YL, Chen Q, Xu JJ, Paterakis G, Dracopoulos V, Xu ZX, Tasis D, Mohammadi MR, Lianos P. Introduction of Graphene Oxide as Buffer Layer in Perovskite Solar Cells and the Promotion of Soluble n-Butyl-substituted Copper Phthalocyanine as Efficient Hole Transporting Material. Electrochim Acta 2017. [DOI: 10.1016/j.electacta.2017.03.027] [Citation(s) in RCA: 46] [Impact Index Per Article: 6.6] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/29/2022]
|
19
|
Giannopoulos G, Vrachatis DA, Oudatzis G, Paterakis G, Angelidis C, Koutivas A, Sianos G, Cleman MW, Filippatos G, Lekakis J, Deftereos S. Circulating Erythrocyte Microparticles and the Biochemical Extent of Myocardial Injury in ST Elevation Myocardial Infarction. Cardiology 2016; 136:15-20. [DOI: 10.1159/000447625] [Citation(s) in RCA: 8] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Abstract] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 12/28/2015] [Accepted: 05/09/2016] [Indexed: 01/28/2023]
Abstract
Objectives: Red blood cell microparticles (RBCm) have potential adverse vascular effects and they have been shown to be elevated in ST elevation myocardial infarction (STEMI). The purpose of this study is to investigate their relationship with biochemical infarct size. Methods: RBCm were quantified with flow cytometry in blood drawn from 60 STEMI patients after a primary angioplasty. The creatine kinase-myocardial brain fraction (CK-MB) was measured at predefined time points and the area under the curve (AUC) was calculated. Results: RBCm count was correlated with CK-MB AUC (Spearman's ρ = 0.83, p < 0.001). The CK-MB AUC values per RBCm quartile (lower to upper) were: 3,351 (2,452-3,608), 5,005 (4,450-5,424), 5,903 (4,862-10,594), and 8,406 (6,848-12,782) ng × h/ml, respectively. From lower to upper quartiles, the maximal troponin I values were: 42.2 (23.3-49.3), 49.6 (28.8-54.1), 59.2 (41.4-77.3), and 69.1 (48.0-77.5) ng/ml (p = 0.005). In multivariable analysis, RBCm remained a significant predictor of CK-MB AUC (standardized β = 0.63, adjusted p = 0.001). Conclusions: Erythrocyte microparticles appear to be related to the total myocardial damage biomarker output. The exact pathophysiologic routes, if any, for this interaction remain to be identified. However, these results suggest that erythrocytes may be a - thus far virtually ignored - player in the pathogenesis of ischemic injury.
Collapse
|
20
|
Belekoukia M, Ramasamy MS, Yang S, Feng X, Paterakis G, Dracopoulos V, Galiotis C, Lianos P. Electrochemically exfoliated graphene/PEDOT composite films as efficient Pt-free counter electrode for dye-sensitized solar cells. Electrochim Acta 2016. [DOI: 10.1016/j.electacta.2016.02.073] [Citation(s) in RCA: 34] [Impact Index Per Article: 4.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/22/2022]
|
21
|
Sekkarapatti Ramasamy M, Nikolakapoulou A, Raptis D, Dracopoulos V, Paterakis G, Lianos P. Reduced graphene oxide/Polypyrrole/PEDOT composite films as efficient Pt-free counter electrode for dye-sensitized solar cells. Electrochim Acta 2015. [DOI: 10.1016/j.electacta.2015.05.043] [Citation(s) in RCA: 59] [Impact Index Per Article: 6.6] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/27/2022]
|
22
|
Kostopoulos IV, Paterakis G, Papadimitriou K, Pavlidis D, Tsitsilonis OE, Papadhimitriou SI. Immunophenotypic analysis reveals heterogeneity and common biologic aspects in monoclonal B-cell lymphocytosis. Genes Chromosomes Cancer 2014; 54:210-21. [PMID: 25533355 DOI: 10.1002/gcc.22234] [Citation(s) in RCA: 11] [Impact Index Per Article: 1.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/14/2014] [Accepted: 11/28/2014] [Indexed: 02/02/2023] Open
Abstract
Monoclonal B-cell lymphocytosis (MBL) is the presence of small B-cell clones in the peripheral blood of healthy subjects. Most MBL have the characteristic phenotype of chronic lymphocyte leukemia (chronic lymphocytic leukemia (CLL)-like MBL), and depending on the number of monoclonal B-cells, may characterize a preclinical stage of the CLL. However, there are also MBL with an atypical (CD5(+) CD20(+/bright) CD23(dim/-) ) or a CD5(neg) phenotype, which remain largely unexplored. We performed an extended immunophenotypic, cytogenetic, and hematologic analysis in 75 CLL-like, 39 atypical, 50 CD5(neg) , and 7 biphenotypic MBL cases to detect differences or similarities among the MBL subsets. The phenotypic analysis showed expression variations in many surface markers and a wide spectrum of disease-specific phenotypes within each MBL subtype. Interphase fluorescent in situ hybridization analysis showed a different panel of aberrations according to the phenotype. Overall, del(13q14) and +12 were the most common abnormalities (39%), whereas del(11q13), del(17p13), and del(6q23) were detected only in 3, 1, and 0 cases, respectively. A comparison of MBL with overt chronic lymphoproliferations revealed common aspects in the preclinical state, regarding both the kind of cytogenetic aberrations detected and the lymphocyte composition. Our findings highlight not only the heterogeneity among MBL subsets but also indicate common biologic features which differentiate MBL from clinical disease.
Collapse
Affiliation(s)
- Ioannis V Kostopoulos
- Haematology Laboratory, "G. Gennimatas" Athens Regional General Hospital, Athens, Greece; Department of Animal and Human Physiology, Faculty of Biology, National and Kapodistrian University of Athens, Athens, Greece
| | | | | | | | | | | |
Collapse
|
23
|
Giannopoulos G, Oudatzis G, Paterakis G, Synetos A, Tampaki E, Bouras G, Hahalis G, Alexopoulos D, Tousoulis D, Cleman MW, Stefanadis C, Deftereos S. Red blood cell and platelet microparticles in myocardial infarction patients treated with primary angioplasty. Int J Cardiol 2014; 176:145-50. [PMID: 25062560 DOI: 10.1016/j.ijcard.2014.07.022] [Citation(s) in RCA: 52] [Impact Index Per Article: 5.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 05/07/2014] [Accepted: 07/05/2014] [Indexed: 01/28/2023]
Abstract
BACKGROUND Red blood cell and platelet microparticles (RBCm and PLTm, respectively) have drawn research attention as to their potential prothrombotic and vasoconstrictive effects in experimental settings. However, the relevance of circulating microparticles in clinical settings is largely undetermined. METHODS Circulating microparticles were quantified with a flow cytometric method in blood samples from consecutive STEMI patients after primary PCI. A matched cohort of healthy volunteers was used to derive reference values for comparison. STEMI patients were followed for 6 months for a composite clinical endpoint. RESULTS Fifty-one STEMI patients (age 59.8 ± 8.8 years) and 50 controls (age 56.2 ± 9.2 years; p=0.155) were enrolled. RBCm concentration was 18,198 ± 6062/μl in the reference cohort versus 33,740 ± 21,169/μl in STEMI patients (p<0.001). RBCm count was not correlated to total RBCs (standardized beta 0.018; p=0.861). PLTm did not differ between groups (17,529 ± 16,292/μl in STEMI patients versus 14,372 ± 6211/μl in controls; p=0.203). RBCm c-statistic was 0.832 (95% confidence interval 0.720 to 0.944), while PLTm prognostic value was not statistically significant (c-statistic 0.614, 95% confidence interval 0.444 to 0.784). In the multivariate analysis, RBCm concentration was independently associated with the occurrence of the clinical endpoint, after adjustment for age, ejection fraction, serum creatinine and presence of diabetes (adjusted p=0.034). CONCLUSIONS The present study demonstrates for the first time that erythrocyte microparticles are elevated in patients with STEMI treated with primary PCI, with levels approximately double those measured in a reference population of healthy volunteers, and their concentrations appear to be positively associated with adverse clinical events.
Collapse
Affiliation(s)
- Georgios Giannopoulos
- Cardiac Catheterization Laboratory, Department of Cardiology, Athens General Hospital "G. Gennimatas", Athens, Greece; Section of Cardiovascular Medicine, Yale University School of Medicine, New Haven, CT, USA.
| | - Georgios Oudatzis
- Flow Cytometry Laboratory, Department of Immunology, Athens General Hospital "G. Gennimatas", Athens, Greece
| | - Georgios Paterakis
- Flow Cytometry Laboratory, Department of Immunology, Athens General Hospital "G. Gennimatas", Athens, Greece
| | - Andreas Synetos
- 1st Department of Cardiology, University of Athens Medical School, Athens, Greece
| | - Eleni Tampaki
- Cardiac Catheterization Laboratory, Department of Cardiology, Athens General Hospital "G. Gennimatas", Athens, Greece
| | - Georgios Bouras
- Cardiac Catheterization Laboratory, Department of Cardiology, Athens General Hospital "G. Gennimatas", Athens, Greece
| | - George Hahalis
- Department of Cardiology, University of Patras Medical School, Patras, Greece
| | | | - Dimitrios Tousoulis
- 1st Department of Cardiology, University of Athens Medical School, Athens, Greece
| | - Michael W Cleman
- Section of Cardiovascular Medicine, Yale University School of Medicine, New Haven, CT, USA
| | | | - Spyridon Deftereos
- Cardiac Catheterization Laboratory, Department of Cardiology, Athens General Hospital "G. Gennimatas", Athens, Greece; Section of Cardiovascular Medicine, Yale University School of Medicine, New Haven, CT, USA
| |
Collapse
|
24
|
Ampatzidou M, Panagiotou JP, Paterakis G, Papadakis V, Papadhimitriou SI, Parcharidou A, Papargyri S, Rigatou E, Avgerinou G, Tsitsikas K, Vasdekis V, Haidas S, Polychronopoulou S. Childhood acute lymphoblastic leukemia: 12 years of experience, using a Berlin-Frankfurt-Münster approach, in a Greek center. Leuk Lymphoma 2014; 56:251-5. [PMID: 24766491 DOI: 10.3109/10428194.2014.916801] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/13/2022]
Affiliation(s)
- Maria Ampatzidou
- Department of Pediatric Hematology-Oncology, "Aghia Sophia" Children's Hospital , Athens , Greece
| | | | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|
25
|
Kanakoudi-Tsakalidou F, Farmaki E, Tzimouli V, Taparkou A, Paterakis G, Trachana M, Pratsidou-Gertsi P, Nalbanti P, Papachristou F. Simultaneous changes in serum HMGB1 and IFN-α levels and in LAIR-1 expression on plasmatoid dendritic cells of patients with juvenile SLE. New therapeutic options? Lupus 2014; 23:305-12. [PMID: 24399813 DOI: 10.1177/0961203313519157] [Citation(s) in RCA: 24] [Impact Index Per Article: 2.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/15/2022]
Abstract
We investigated the simultaneous changes in serum levels of HMGB1 and IFN-α as well as in LAIR-1 expression on plasmatoid dendritic cells (pDCs) of juvenile systemic lupus erythematosus (jSLE) patients in order to explore their involvement in the disease pathogenesis and their correlation with disease activity and other characteristics. In total, 62 blood samples were studied from 26 jSLE patients (18 girls), aged 8-16 years. Twenty healthy subjects (16 girls) of comparable age were included as healthy controls (HCs). Concentrations of serum HMGB1 and IFN-α were assessed by ELISA and LAIR-1 expression on pDCs by five-color flow cytometry. The disease activity index was assessed by SLEDAI and ECLAM scores. It was found that mean serum levels both of HMGB1 and IFN-α were significantly increased in jSLE patients compared to HCs and in jSLE patients with active disease with or without active nephritis compared to those with inactive disease. Mean serum levels of HMGB1 were positively correlated with levels of IFN-α and both were positively correlated with the SLEDAI and ECLAM scores. The expression of LAIR -1 on pDCs of jSLE patients was significantly lower than that of HCs. In conclusion, our findings indicate that serum HMGB1 not only represents a potential marker of disease activity but together with the lack of LAIR-1 inhibitory function may contribute to the sustained inflammatory action of IFN-α in jSLE. In this regard, blocking the action of HMGB1 and its receptors or enhancing the expression/inhibitory function of LAIR-1 on pDCs should be included in future immune interventions for controlling jSLE.
Collapse
Affiliation(s)
- F Kanakoudi-Tsakalidou
- 1First Department of Pediatrics, Pediatric Immunology and Rheumatology Referral Centre, Aristotle University, "Hippokration" General Hospital, Thessaloniki, Greece
| | | | | | | | | | | | | | | | | |
Collapse
|
26
|
Marousi S, Karkanis I, Kalamatas T, Travasarou M, Paterakis G, Karageorgiou CE. Immune cells after prolonged Natalizumab therapy: implications for effectiveness and safety. Acta Neurol Scand 2013; 128:e1-5. [PMID: 23311457 DOI: 10.1111/ane.12080] [Citation(s) in RCA: 13] [Impact Index Per Article: 1.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Accepted: 12/05/2012] [Indexed: 11/29/2022]
Abstract
BACKGROUND Previous studies on Natalizumab (NAT) have shown increased circulation of most white blood cells (WBC) in multiple sclerosis (MS) patients shortly after its introduction. AIM To describe peripheral immune cell phenotypes after more than 2 years of continuous NAT therapy and test for associations with clinical response to therapy. METHODS Peripheral immune cell subsets were analyzed in 44 NAT-MS patients receiving NAT for over 24 months, and in 22 NAT-free control-MS patients. RESULTS NAT-MS patients displayed significantly higher numbers of all WBC when compared with controls. B lymphocytes exhibited a more pronounced increase when compared with CD4+, CD8+ and NK T-cells (P = 0.011). CD4/CD8 ratio was significantly decreased in NAT-MS patients (P = 0.018) and showed no correlation with the number of NAT doses. The reduced CD4/CD8 ratio was attributable to the 'EDSS improvement' group only, irrespective of age, sex and disease severity. CONCLUSIONS The study suggests that there is no desensitization effect after prolonged NAT exposure. A reduced CD4/CD8 ratio was associated with long-term response to therapy; thus, those patients who most benefitted from the drug might be at greater risk for opportunistic infections like progressive multifocal leucoencephalopathy (PML). We provide implications for future research for the CD4/CD8 ratio as a possible contributor to the recently developed risk stratification scheme for PML.
Collapse
Affiliation(s)
- S. Marousi
- Department of Neurology; ‘G. Gennimatas’ General Hospital of Athens; Athens; Greece
| | - I. Karkanis
- Department of Neurology; ‘G. Gennimatas’ General Hospital of Athens; Athens; Greece
| | - T. Kalamatas
- Department of Neurology; ‘G. Gennimatas’ General Hospital of Athens; Athens; Greece
| | - M. Travasarou
- Department of Neurology; ‘G. Gennimatas’ General Hospital of Athens; Athens; Greece
| | - G. Paterakis
- Department of Heamatology; ‘G. Gennimatas’ General Hospital of Athens; Athens; Greece
| | - C. E. Karageorgiou
- Department of Neurology; ‘G. Gennimatas’ General Hospital of Athens; Athens; Greece
| |
Collapse
|
27
|
Tsagarakis NJ, Kentrou NA, Papadimitriou KA, Pagoni M, Kokkini G, Papadaki H, Pappa V, Marinakis T, Anagnostopoulos NI, Vadikolia C, Anagnostopoulos A, Angelopoulou MK, Terpos E, Poziopoulos C, Anargyrou K, Rontogianni D, Papadaki T, Psarra A, Kontopidou FN, Skoumi D, Papadhimitriou SI, Paterakis G. Acute lymphoplasmacytoid dendritic cell (DC2) leukemia: Results from the Hellenic Dendritic Cell Leukemia Study Group. Leuk Res 2010; 34:438-46. [DOI: 10.1016/j.leukres.2009.09.006] [Citation(s) in RCA: 73] [Impact Index Per Article: 5.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/12/2009] [Revised: 09/05/2009] [Accepted: 09/05/2009] [Indexed: 01/29/2023]
|
28
|
Kaloyannidis P, Zomas A, Paterakis G, Vadikoliou C, Mallouri D, Sakkas L, Sakellari I. GVL effect in plasmacytoid DC leukemia/lymphoma. Bone Marrow Transplant 2009; 45:961-2. [DOI: 10.1038/bmt.2009.270] [Citation(s) in RCA: 6] [Impact Index Per Article: 0.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/09/2022]
|
29
|
Gogali F, Foifa K, Vasileiou-Pateraki P, Paterakis G. A novel NK cell population with cytoplasmic CD3ɛ expression, is increased in cord blood as well as in peripheral blood of women with recurrent spontaneous abortions (RSA). J Reprod Immunol 2009. [DOI: 10.1016/j.jri.2009.06.237] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/20/2022]
|
30
|
Tsagarakis NJ, Argyrou A, Gortzolidis G, Kentrou N, Papadhimitriou SI, Tzanetou K, Kakiopoulos G, Papadimitriou KA, Skoumi D, Paterakis G. Report of an HIV and HHV-8 negative case of primary effusion lymphoma with idiopathic T4 lymphocytopenia. Int J Hematol 2009; 90:94-98. [PMID: 19484335 DOI: 10.1007/s12185-009-0343-0] [Citation(s) in RCA: 20] [Impact Index Per Article: 1.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/15/2009] [Revised: 04/27/2009] [Accepted: 04/30/2009] [Indexed: 11/28/2022]
Abstract
Although primary effusion lymphoma (PEL) is usually associated with human herpes virus-8/Kaposi sarcoma herpes virus (HHV-8/KSHV) and human immunodeficiency virus (HIV), there are several reports of HHV-8/KSHV and HIV negative cases, mainly in the setting of immunodeficiency. Here, we report the second case of PEL associated with idiopathic T4 lymphocytopenia (ICL), which was HHV-8/KSHV negative, HIV negative and Epstein-Barr virus positive, while no other causative agents for immunodeficiency were documented. Flow cytometry revealed a hyperdiploid and highly mitotic large B-cell population, CD30, EMA, CD66, CD38 and CD71 positive. The malignant lymphoma cells showed atypia with prominent nuclei and basophilic vacuolated cytoplasm, while cytogenetic analysis with fluorescent in situ hybridization showed trisomy 18. The patient was administered R-COP chemotherapy, but no remission was achieved, up to 3 months from diagnosis.
Collapse
Affiliation(s)
- Nikolaos J Tsagarakis
- Flow Cytometry Laboratory, Department of Immunology, Athens Regional General Hospital "G. Gennimatas", Mesogion Avenue 154, 11527, Athens, Greece.
| | - Aspasia Argyrou
- Department of Clinical Hematology, Athens Regional General Hospital "G. Gennimatas", Athens, Greece
| | - Georgios Gortzolidis
- Department of Clinical Hematology, Athens Regional General Hospital "G. Gennimatas", Athens, Greece
| | - Nektaria Kentrou
- Flow Cytometry Laboratory, Department of Immunology, Athens Regional General Hospital "G. Gennimatas", Mesogion Avenue 154, 11527, Athens, Greece
| | - Stefanos I Papadhimitriou
- Department of Laboratory Hematology, Athens Regional General Hospital "G. Gennimatas", Athens, Greece
| | - Konstantina Tzanetou
- Department of Microbiology, Athens Regional General Hospital "G. Gennimatas", Athens, Greece
| | - Georgios Kakiopoulos
- Department of Pathology, Athens Regional General Hospital "G. Gennimatas", Athens, Greece
| | - Konstantinos A Papadimitriou
- Flow Cytometry Laboratory, Department of Immunology, Athens Regional General Hospital "G. Gennimatas", Mesogion Avenue 154, 11527, Athens, Greece
| | - Dimitra Skoumi
- Flow Cytometry Laboratory, Department of Immunology, Athens Regional General Hospital "G. Gennimatas", Mesogion Avenue 154, 11527, Athens, Greece
| | - Georgios Paterakis
- Flow Cytometry Laboratory, Department of Immunology, Athens Regional General Hospital "G. Gennimatas", Mesogion Avenue 154, 11527, Athens, Greece
| |
Collapse
|
31
|
Marinos L, Economaki E, Stavroyianni N, Papadaki C, Xylouri I, Lalayanni C, Paterakis G, Pouliou E, Athanasiadou A, Kokkini G, Papadaki H, Fassas A, Anagnostopoulos A, Stamatopoulos K, Papadaki T. P082 Hematological manifestations and histopathological findings in T-large granular lymphocyte leukemia. Leuk Res 2009. [DOI: 10.1016/s0145-2126(09)70162-6] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/15/2022]
|
32
|
Papassavas AC, Gioka V, Chatzistamatiou T, Kokkinos T, Anagnostakis I, Gecka G, Redoukas I, Paterakis G, Stavropoulos-Giokas C. A strategy of splitting individual high volume cord blood units into two half subunits prior to processing increases the recovery of cells and facilitates ex vivo expansion of the infused haematopoietic progenitor cells in adults. Int J Lab Hematol 2008; 30:124-32. [PMID: 18333844 DOI: 10.1111/j.1751-553x.2007.00906.x] [Citation(s) in RCA: 16] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/29/2022]
Abstract
This study was designed to maximize the recovery of the desirable cell populations contained in the cord blood (CB) freezing bag, in order to optimize donor selection for adolescents and adults. To evaluate this hypothesis, high volume CB units (CBUs) were categorized into three volume collection groups (120-139, 140-159 and >or=160 ml) and were randomly split before volume reduction into two half low volume CBUs; (a) and (b). Using the SEPAX Cell Processing System, all CBUs were standardized to 26 ml. In 128 high volume split CBUs, the WBC, mononuclear cell and CD34+ cell recoveries were significantly higher (P
Collapse
Affiliation(s)
- A C Papassavas
- Hellenic Cord Blood Bank, Foundation for Biomedical Research, Academy of Athens, Athens, Greece.
| | | | | | | | | | | | | | | | | |
Collapse
|
33
|
Stamatopoulos K, Papadaki T, Pontikoglou C, Athanasiadou I, Stavroyianni N, Bux J, Batsis I, Pyrovolaki K, Paterakis G, Anagnostou D, Anagnostopoulos A, Papadaki HA. Lymphocyte subpopulation imbalances, bone marrow hematopoiesis and histopathology in rituximab-treated lymphoma patients with late-onset neutropenia. Leukemia 2008; 22:1446-9. [PMID: 18185527 DOI: 10.1038/sj.leu.2405077] [Citation(s) in RCA: 35] [Impact Index Per Article: 2.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/21/2022]
|
34
|
Xanthopoulos V, Galanopoulos AG, Paterakis G, Apessou D, Argyrakos T, Goumakou E, Papadhimitriou SI, Savvidou I, Georgiakaki M, Anagnostopoulos NI. Intravascular B-cell lymphoma with leukemic presentation: case report and literature review. Eur J Haematol 2007; 80:177-81. [PMID: 18076638 DOI: 10.1111/j.1600-0609.2007.00984.x] [Citation(s) in RCA: 6] [Impact Index Per Article: 0.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/27/2022]
Abstract
Intravascular lymphoma is an extremely rare, disseminated, and aggressive extranodal CD20+ non-Hodgkin's lymphoma characterized by the presence of lymphoma cells only in the lumina of small vessels. We report a 72-year-old woman with a diagnosis of intravascular lymphoma presented with splenomegaly and leukemic appearance in the peripheral blood smear. Her clinical course was rapidly deteriorated before the initiation of specific chemotherapy and finally died due to multiorgan insufficiency. Bone marrow biopsy revealed a characteristic infiltration of CD5, CD10 B-cell lymphoma. To our knowledge, this is the first reported case of a CD5, CD10 intravascular B-cell lymphoma with leukemic presentation in peripheral blood with multiple cytogenetic aberrations.
Collapse
|
35
|
Passam F, Tachynopoulou V, Skoumi D, Tsompanakou A, Stavropoulos-Giokas A, Vadikolia C, Anagnostopoulos A, Paterakis G. Feasibility of an easily applicable method of ZAP-70 measurement in chronic lymphocytic leukemia in the routine flow cytometry setting: A methodological approach. Ann Hematol 2006; 85:795-805. [PMID: 16871389 DOI: 10.1007/s00277-006-0159-4] [Citation(s) in RCA: 6] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/20/2006] [Accepted: 06/01/2006] [Indexed: 12/01/2022]
Abstract
Zeta-associated protein 70 (ZAP-70), determined by flow cytometry, has been advocated a surrogate marker of immunoglobulin (Ig)V(H) unmutated status in B chronic lymphocytic leukemia (CLL). The aim of the current study was to test the applicability of an easy flow cytometry protocol for ZAP-70 measurement in CLL samples. Samples from 61 CLL patients and 44 normal subjects were analyzed using a commercial ZAP-70 monoclonal antibody (1E7.2 clone) conjugated with phycoerythrin (PE) and Alexa 488 fluorochromes. Modifications of the published methods led to the structure of a simplified in-house method of ZAP-70 measurement. A three-color approach was used with CD19, CD3 gating comparing with the isotype control provided by the same manufacturer. The cutoff levels for ZAP-70 positivity were defined from a receiver operator characteristic curve in relation to the IgV(H) mutational status and from the ln normalized mean value +2 SD of normal controls. Using the 20% cutoff value for ZAP-70 positivity in CLL patients defined by the literature, ZAP-PE had a sensitivity of 55% and a specificity of 98% in predicting the IgV(H) mutational status, whereas the corresponding values for ZAP-Alexa were 55% and 84%, respectively. Using the 7% cutoff value for CD38 positivity, the sensitivity was 55%, whereas the specificity was 76%. ZAP-70-positive patients showed a shorter time to disease progression in comparison with ZAP-70-negative patients (p < 0.001). In conclusion, the 100% specific prediction of mutational status is accompanied by reduced sensitivity, thus limiting ZAP-70's applicability either as a single marker or combined with CD38 for the assessment of the mutational status of CLL.
Collapse
MESH Headings
- ADP-ribosyl Cyclase 1/analysis
- Adult
- Aged
- Antigens, CD19
- Biomarkers/analysis
- CD3 Complex
- Case-Control Studies
- Disease Progression
- Feasibility Studies
- Female
- Flow Cytometry/methods
- Flow Cytometry/standards
- Humans
- Leukemia, Lymphocytic, Chronic, B-Cell/diagnosis
- Leukemia, Lymphocytic, Chronic, B-Cell/enzymology
- Leukemia, Lymphocytic, Chronic, B-Cell/mortality
- Lymphocytes
- Male
- Methods
- Middle Aged
- Prognosis
- ROC Curve
- Reference Standards
- Survival Analysis
- ZAP-70 Protein-Tyrosine Kinase/analysis
Collapse
Affiliation(s)
- Freda Passam
- Immunology Department and National Histocompatibility Centre, G Gennimatas General Hospital, Athens, Greece
| | | | | | | | | | | | | | | |
Collapse
|
36
|
Goussetis E, Spiropoulos A, Theodosaki M, Paterakis G, Peristeri I, Kitra V, Petrakou E, Soldatou A, Graphakos S. Culture of bone marrow CD105+ cells allows rapid selection of pure BM-stromal cells for chimerism studies in patients undergoing allogeneic bone marrow transplantation. Bone Marrow Transplant 2005; 36:557-9. [PMID: 16025154 DOI: 10.1038/sj.bmt.1705083] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [What about the content of this article? (0)] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/08/2022]
|
37
|
Chatzistamatiou T, Paterakis G, Stavropoulos-Giokas C, Papassavas A. Sufficient numbers of cord blood derived mesenhymal stem cells for transplantation are generated by plastic adhesion or depleting methods. Biol Blood Marrow Transplant 2005. [DOI: 10.1016/j.bbmt.2004.12.211] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/25/2022]
|
38
|
Bakas P, Liapis A, Giner M, Paterakis G, Creatsas G. Massive fetomaternal hemorrhage and oxytocin contraction test: case report and review. Arch Gynecol Obstet 2004; 269:149-51. [PMID: 14648183 DOI: 10.1007/s00404-002-0431-3] [Citation(s) in RCA: 6] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/17/2002] [Accepted: 08/27/2002] [Indexed: 10/26/2022]
Abstract
We present a case of a nulliparous woman who underwent oxytocin contraction test because of abnormal cardiotocograph. She delivered a severely anemic neonate due to severe fetomaternal hemorrhage. Fetal ultrasonography and Doppler studies of the umbilical arteries may not be helpful, while its worthy to perform flow cytometry for detection of fetal cells in maternal circulation when there is strong clinical suspicion. Management of massive fetomaternal hemorrhage requires immediate delivery by Caesarean section if the gestational age is suitable. Alternatively, for very premature fetuses could be used serial fetal intravascular transfusions if there are the necessary facilities and experienced personnel.
Collapse
Affiliation(s)
- Panagiotis Bakas
- 2nd Department of Obstetrics and Gynecology, University of Athens, Aretaieio Hospital, Alexandras Avenue 108, Greece 11522.
| | | | | | | | | |
Collapse
|
39
|
Goussetis E, Theodosaki M, Paterakis G, Stefanaki K, Tsecoura C, Papassarandis C, Graphakos S. Kinetics of quiescent cord blood stem/progenitor cells with high proliferative potential in stem-cell expansion culture. Cytotherapy 2003; 5:500-8. [PMID: 14660046 DOI: 10.1080/14653240310003602] [Citation(s) in RCA: 4] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/26/2022]
Abstract
BACKGROUND The most primitive engrafting hematopoietic stem cell (HSC) resides mainly in a tumor growth factor-beta (TGF-beta)-dependent quiescent phase of the cell cycle. In this study, ex vivo expansion of UC blood (UCB) HSCs has been investigated, with the aim of showing whether quiescent HSCs can be recovered from expansion culture. METHODS AC133(+) stem/progenitor cells from six full term-pregnancies UCB-samples were immunomagnetically selected, followed by ex vivo expansion culture in the presence of thrombopoietin (TPO), c-kit ligand (KL), flt-3 ligand (FL) and IL-6. Quiescent HSCs were detected by a clonogenic assay that allows the detection of multipotent and committed single- lineage quiescent stem/progenitor cells, named mHPP-Q and cHPP-Q, respectively, by means of a TGF-beta blocking Ab. RESULTS Expansion culture of fresh selected AC133(+) cells for 1 week caused maintenance rather than expansion of mHPP-Q cells and a 1-fold increase in cHPP-Q cells. A further week culture initiated with 7-day expanded AC133(+) cells resulted in an additional 1.5-fold expansion of cHPP-Q while no mHPP-Q cells could be detected. Amplification of cHPP-Q cells in long-term expansion cultures initiated with 14-day expanded AC133(+) cells was observed for at least a further 4 weeks. DISCUSSION A small proportion of HPP-Q cells recovered from 7-day expansion cultures retain their multilineage potential: longer culturing of these cells results in the loss of multilineage potential while they maintain quiescent behavior and high proliferative potential.
Collapse
Affiliation(s)
- E Goussetis
- Stem Cell Transplant Unit, 'Aghia Sophia' Children's Hospital, Athens, Greece
| | | | | | | | | | | | | |
Collapse
|
40
|
Tsantes A, Androutsos G, Bonovas S, Vogiatzi D, Meletis I, Stamou E, Stamoulakatou A, Paterakis G. Assessment of a new immunocytochemical technique in HbF-cell counting by a novel objective evaluation method. Br J Haematol 2003; 123:948-51. [PMID: 14632788 DOI: 10.1046/j.1365-2141.2003.04717.x] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022]
Abstract
A recently developed immunocytochemical technique in HbF-cell counting was assessed by an objective evaluation method. The basic principle of this method is the preparation of aliquots with predetermined HbF-cell (target) values. These aliquots serve as control samples to standardize the HbF-cell measurements by the new immunocytochemical technique, which uses the StreptABComplex/AP staining procedure (SAP) and visualization under white light. Immunofluorescence optical counts (IF) were performed in parallel with the new technique. A trend of inaccuracy was observed in low target values for both methods. As the level of target values increased, deviations became insignificant (relative accuracy < 8%) with SAP having slightly better results. Linear regression data of the estimated %HbF-cell rates by the two methods versus the target values were very satisfactory for both methods with SAP being slightly better. SAP seems to provide an accurate and reliable alternative for HbF-cell estimation comparable with the classical IF optical count.
Collapse
Affiliation(s)
- Argirios Tsantes
- Department of Haematology, General Hospital of Athens "G. Gennimatas", Athens, Greece
| | | | | | | | | | | | | | | |
Collapse
|
41
|
Anargyrou K, Paterakis G, Boutsis D, Politou M, Papadhimitriou SI, Siakandaris M, Vassiliadis J, Androulakis A, Meletis J, Rombos J, Tassiopoulou A, Vaiopoulos G. An unusual case of CD4+ CD7+ CD56+ acute leukemia with overlapping features of type 2 dendritic cell (DC2) and myeloid/NK cell precursor acute leukemia. Eur J Haematol 2003; 71:294-8. [PMID: 12950240 DOI: 10.1034/j.1600-0609.2003.00098.x] [Citation(s) in RCA: 19] [Impact Index Per Article: 0.9] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/23/2022]
Abstract
Type 2 dendritic cell (DC2) acute leukemia has been recently described. We report here an unusual case of a 17-yr-old adolescent with overlapping features of DC2 and myeloid/NK cell precursor acute leukemia as defined by Suzuki et al. The patient presented with lymphadenopathy and hepatosplenomegaly without extranodal manifestations in skin or elsewhere. The morphologic, cytochemical and immunophenotypic features were compatible with those described in DC2 acute leukemia, with co-expression of CD4, CD56 and CD123 antigens. The novel markers BDCA-4 and BDCA-2 considered specific for DC2s were co-expressed. However, bright CD7 positivity along with a dim expression of CD33 (57%) and CD117 (27%) were also noted. Additionally, there was bright expression of NG2 monoclonal antibody 7.1, a frequent finding in myeloid/NK cell precursor acute leukemia. The interpretation of the immunophenotypic profile leads to the hypothesis on the existence of borderline cases between DC2 and myeloid/NK cell precursor acute leukemia. Still, other hypotheses can not be overlooked, such as the possibility for a kind of variant monoblastic leukemia or of another rare entity of acute unclassified leukemia.
Collapse
MESH Headings
- Adolescent
- Antigens, CD/biosynthesis
- Antigens, CD7/biosynthesis
- Antigens, Differentiation, Myelomonocytic/biosynthesis
- Antigens, Surface/blood
- Bone Marrow Cells
- CD4 Antigens/biosynthesis
- CD56 Antigen/biosynthesis
- Dendritic Cells/cytology
- Flow Cytometry
- Humans
- Immunophenotyping
- Killer Cells, Natural/cytology
- Lectins, C-Type/blood
- Leukemia/blood
- Leukemia/metabolism
- Leukemia, Myeloid, Acute/blood
- Leukocyte Common Antigens/biosynthesis
- Male
- Membrane Glycoproteins
- Proto-Oncogene Proteins c-kit/biosynthesis
- Receptors, Immunologic
- Sialic Acid Binding Ig-like Lectin 3
Collapse
Affiliation(s)
- K Anargyrou
- First Department of Internal Medicine, Laikon General Hospital, University of Athens, Athens, Greece
| | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|
42
|
Polychronopoulou S, Tsatsopoulou A, Papadhimitriou SI, Panagiotou JP, Anastasakis A, Paterakis G, Anagnostou D, Protonotarious N, Haidas SA. Myelodysplasia and Naxos disease: a novel pathogenetic association? Leukemia 2002; 16:2335-7. [PMID: 12399983 DOI: 10.1038/sj.leu.2402587] [Citation(s) in RCA: 5] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [What about the content of this article? (0)] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/26/2001] [Accepted: 04/11/2002] [Indexed: 11/09/2022]
|
43
|
Papadaki T, Stamatopoulos K, Kosmas C, Paterakis G, Kapsimali V, Kokkini G, Economopoulos T, Stefanoudaki-Sofianatou K, Marinakis T, Gardikas E, Kalmantis T. Clonal T-large granular lymphocyte proliferations associated with clonal B cell lymphoproliferative disorders: report of eight cases. Leukemia 2002; 16:2167-9. [PMID: 12357377 DOI: 10.1038/sj.leu.2402643] [Citation(s) in RCA: 28] [Impact Index Per Article: 1.3] [Reference Citation Analysis] [What about the content of this article? (0)] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/09/2002] [Accepted: 05/14/2002] [Indexed: 11/09/2022]
|
44
|
Papadaki T, Stamatopoulos K, Stavroyianni N, Paterakis G, Phisphis M, Stefanoudaki-Sofianatou K. Evidence for T-large granular lymphocyte-mediated neutropenia in Rituximab-treated lymphoma patients: report of two cases. Leuk Res 2002; 26:597-600. [PMID: 12007508 DOI: 10.1016/s0145-2126(01)00183-7] [Citation(s) in RCA: 60] [Impact Index Per Article: 2.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/27/2022]
Abstract
We report two cases with B cell malignancies (case #1: refractory mantle cell lymphoma; case #2: lymphocyte predominant Hodgkin's disease (LPHD)) who developed neutropenia post-Rituximab therapy in a setting of significant infiltration of the peripheral blood (PB) and bone marrow (BM) by T cells with an immunophenotype of large granular lymphocytes. Possible pathogenetic mechanisms are discussed.
Collapse
Affiliation(s)
- T Papadaki
- Hemopathology Unit, Evangelismos Hospital, Athens, Greece
| | | | | | | | | | | |
Collapse
|
45
|
Psiachou-Leonard E, Paterakis G, Stefanaki K, Mikraki-Christou V, Haidas S. Cerebellar granulocytic sarcoma in an infant with CD56+ acute monoblastic leukemia. Leuk Res 2001; 25:1019-21. [PMID: 11597737 DOI: 10.1016/s0145-2126(01)00068-6] [Citation(s) in RCA: 19] [Impact Index Per Article: 0.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/18/2022]
Abstract
Granulocytic sarcoma (GS) is a form of extramedullary leukaemia (EML). The presence of the neural cell adhesion molecule (NCAM) on the surface of the blasts, which is recognized by the CD56 monoclonal antibody, enhances their propensity for tissue penetration. GS within the central nervous system (CNS), in particular within the cerebellum, is extremely uncommon. We review the literature and describe an infant with isolated cerebellar GS relapse, which antedated a CD56+ acute monoblastic leukaemia bone marrow (BM) relapse.
Collapse
Affiliation(s)
- E Psiachou-Leonard
- Department of Haematology-Oncology, Aghia Sophia Children's Hospital, Thivon & Papadiamanto-poulou, 11527, Athens, Greece.
| | | | | | | | | |
Collapse
|
46
|
Kollia P, Stavroyianni N, Stamatopoulos K, Zoi K, Viniou N, Mantzourani M, Noguchi CT, Paterakis G, Abazis D, Pangalos C, Loukopoulos D, Yataganas X. Molecular analysis of transferrin receptor mRNA expression in acute myeloid leukaemia. Br J Haematol 2001; 115:19-24. [PMID: 11722405 DOI: 10.1046/j.1365-2141.2001.03065.x] [Citation(s) in RCA: 14] [Impact Index Per Article: 0.6] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022]
Abstract
Transferrin receptor (TfR, CD71) is an integral membrane glycoprotein that mediates cellular uptake of iron. In most tissues, TfR expression is correlated positively with proliferation and regulated at the post-transcriptional level. The available data regarding the pattern of TfR gene expression in haematological malignancies are very limited. In the present study, we evaluated TfR gene expression at the molecular level in bone marrow (BM) samples of 44 patients with de novo acute myeloid leukaemia (AML) at diagnosis with BM blasts > 85%. TfR mRNA levels were determined by densitometric analysis of quantitative reverse transcription polymerase chain reaction products corresponding to TfR exons 15-17. Each sample was tested in at least two independent experiments. In 13/44 patients, TfR messages were not detected (this is probably an underestimate as some positive results may be attributed to residual normal erythroid cells present in the samples). In 17/44, TfR mRNA levels were low-intermediate, and were high in the remaining patients (14/44). TfR mRNA positivity was significantly associated with older age. No statistically significant correlations were found either with specific French-American-British (FAB) subtypes or attainment of complete remission, incidence of relapse and survival (after adjusting accordingly for age and FAB subtype). The absence of TfR mRNA transcripts in a significant minority of cases suggests that alternative mechanisms of iron uptake may function in AML blast cells.
Collapse
Affiliation(s)
- P Kollia
- Department of Biology, University of Thessaly Medical School, Larissa, Greece.
| | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|
47
|
Abstract
Multiple myeloma (MM) remains an incurable disease by conventional therapy. MM tumor cells evade the immune system and can induce immunosuppression by producing immunomodifying agents such as TGF-beta, FasL, vascular endothelial growth factor and Muc-1. In the present study, we show that bone marrow cells from a patient suffering from MM IgG/k type, stage IIIA, when cultured, expressed granzyme B and perforin, normally expressed exclusively by cytotoxic T cells (CTLs) and natural killer (NK) cells. In addition, phenotypic analysis revealed that the cultured cells were activated antigen-presenting cells with NK targeting capacity. We propose that expression of these cytolytic enzymes may constitute an additional adoptive mechanism by the tumor cells to actively destroy the host immune effector cells.
Collapse
Affiliation(s)
- I Xagoraris
- Experimental Haematology and Transfusion Medicine, Medical School, University of Patras, Patras, Greece
| | | | | | | | | | | |
Collapse
|
48
|
Poulakis N, Androutsos G, Voucouti N, Paterakis G, Loukides S, Kontozoglou T, Bastas A, Bitsakou C, Provata A, Polyzogopoulos D, Tasiopoulou A. Cytokine production by monocytes/macrophages is normal in patients with alveolar proteinosis: a report of two cases. Respiration 2001; 68:224-5. [PMID: 11287842 DOI: 10.1159/000050498] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.0] [Reference Citation Analysis] [What about the content of this article? (0)] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/19/2022] Open
|
49
|
Markomichelakis NN, Zafirakis P, Karambogia-Karefillidi P, Drakoulis N, Vagiakou-Boudri E, Paterakis G, Apostolopoulos M. Herpes simplex virus type 2: a cause of acute retinal necrosis syndrome. Ocul Immunol Inflamm 2001; 9:103-9. [PMID: 11449326 DOI: 10.1076/ocii.9.2.103.3974] [Citation(s) in RCA: 15] [Impact Index Per Article: 0.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/03/2022]
Abstract
PURPOSE To describe a case of herpes simplex virus type 2 (HSV-2) acute retinal necrosis syndrome (ARN) in a 13-year-old immunocompetent girl. METHODS Polymerase chain reaction (PCR), cultures, flow cytometry, and cytology were performed on the vitreous sample. RESULTS Both PCR studies and vitreous cultures revealed HSV-2 as the cause of ARN. Flow cytometry showed CD4+, CD8+, and natural killer cells. The visual outcome of the patient was 20/200. CONCLUSION Successful culture of HSV-2 from the vitreous specimen in a patient with ARN proved HSV-2 to be one of the causes of ARN. The successful culture of HSV-2 has not been previously reported.
Collapse
MESH Headings
- Adolescent
- Antibodies, Viral/analysis
- CD4-Positive T-Lymphocytes/immunology
- CD8-Positive T-Lymphocytes/immunology
- DNA, Viral/analysis
- Eye Infections, Viral/diagnosis
- Eye Infections, Viral/virology
- Female
- Flow Cytometry
- Herpes Genitalis/diagnosis
- Herpes Genitalis/virology
- Herpesvirus 2, Human/genetics
- Herpesvirus 2, Human/immunology
- Herpesvirus 2, Human/isolation & purification
- Humans
- Immunoglobulin M/analysis
- Killer Cells, Natural/immunology
- Polymerase Chain Reaction
- Retinal Detachment/diagnostic imaging
- Retinal Detachment/virology
- Retinal Necrosis Syndrome, Acute/diagnosis
- Retinal Necrosis Syndrome, Acute/virology
- Ultrasonography
- Visual Acuity
- Vitreous Body/virology
Collapse
Affiliation(s)
- N N Markomichelakis
- Department of Ophthalmology, General Hospital of Athens, Athens Medical School, Athens, Greece.
| | | | | | | | | | | | | |
Collapse
|
50
|
Goussetis E, Theodosaki M, Paterakis G, Peristeri J, Petropoulos D, Kitra V, Papassarandis C, Graphakos S. A functional hierarchy among the CD34+ hematopoietic cells based on in vitro proliferative and differentiative potential of AC133+CD34(bright) and AC133(dim/)-CD34+ human cord blood cells. J Hematother Stem Cell Res 2000; 9:827-40. [PMID: 11177594 DOI: 10.1089/152581600750062255] [Citation(s) in RCA: 40] [Impact Index Per Article: 1.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 11/13/2022]
Abstract
The 5-transmembrane receptor AC133 is expressed on a subpopulation of human hematopoietic cells that includes the CD34(bright) cells. We evaluated the developmental potential of AC133+CD34(bright) and AC133(dim/-)CD34+ cells isolated from 5 cord blood (CB) samples by studying the in vitro proliferative and differentiative potential of each population in both progenitor and mature cell expansion cultures. Seven-day culture of AC133+CD34(bright) cells with a cytokine combination favoring primitive progenitor cells causes a significant increase in CD34+, CFU-C and noncycling stem/progenitor cells HPP-Q (High Proliferative Potential-Quiescent), whereas culture of AC133(dim/-)CD34+ cells shows a limited increase in committed progenitor cells only. HPP-Q cells were not found in freshly isolated AC133(dim/-)CD34+ nor in expanded CD34+ cells derived from AC133(dim/-)CD34+ cells. No statistically significant difference was observed between the 1-week expanded AC133+ and the initial AC133+CD34(bright) cells regarding their clonogenic efficiency (CE), while expanded CD34+ cells derived from AC133(dim/-)CD34+ cells exhibited a decreased CE. Subexpansion of the reselected AC133+ derived from AC133+CD34(bright) cells reveals a further increase of stem/progenitor cells and the 14-day expanded AC133+ cells reveal an unchanged CE. Subexpansion of reselected 7-day CD34+ cells derived from AC133(dim/-)CD34+ cells was not possible. Culture of AC133+CD34(bright) cells in cytokines that favor megakaryopoiesis or erythropoiesis resulted in a significant expansion of CD41+ and CD71+ cells, respectively; AC133(dim/-)CD34+, in comparison, showed a limited potential to megakaryocytic differentiation and a decreased production of erythroid cells. Our data indicate that early high proliferating stem/progenitor cells and early committed progenitors are present in AC133+CD34(bright) cells, but not in AC133(dim/-)CD34+ cells; the latter represent late committed progenitors with limited proliferative potential.
Collapse
Affiliation(s)
- E Goussetis
- Bone Marrow Transplantation Unit, St. Sophia Children's Hospital, Thivon and Levadias, Athens 11527, Greece.
| | | | | | | | | | | | | | | |
Collapse
|